

1 **Tubular lysosomes harbor active ion gradients and poise macrophages for phagocytosis.**

2 Bhavyashree Suresh^{1,2}, Anand Saminathan^{1,2,#}, Kasturi Chakraborty^{1,2,3,4,#}, Matthew Zajac^{1,2},
3 Chang Cui^{3,4}, Lev Becker^{*3,4}, Yamuna Krishnan^{*1,2}

4 ¹Department of Chemistry, The University of Chicago, IL, 60637, USA

5 ²Grossman Institute of Neuroscience, Quantitative Biology and Human Behavior, The University
6 of Chicago, Chicago, IL 60637, USA

7 ³Committee on Cancer Biology, Ben May Department for Cancer Research, The University of
8 Chicago, IL, 60637, USA

9 ⁴Ben May Department for Cancer Research, The University of Chicago, Chicago, IL, USA

10 # Equal Contribution, *Correspondence to: yamuna@uchicago.edu; levb@uchicago.edu

11
12
13 This File includes

14 Materials and Methods

15 Supplementary note 1 to 9

16 Figure S1 to S35

17 Tables S1 to S6

18 Caption for Movie S1

19 References

20 **Chemicals and reagents:** All oligonucleotides, were purchased from Integrated DNA
21 Technologies (IDT, USA). Fluorophore labeled oligonucleotides were ethanol precipitated before
22 use. All other oligonucleotides were HPLC purified and used as it is. Oligonucleotides were
23 quantified by UV spectrophotometer (Shimadzu UV-2700), dissolved in milli-q water, aliquoted
24 and stored at -20 °C for further use.

25 Details of the chemicals used in this study are mentioned in table S3 and S5. Maleylated BSA
26 (mBSA) was synthesized as described in previous protocol(1–3).

27 Inhibitors were dissolved in DMSO (67-68-5, Sigma) at concentrations of 3 mM, stored at -20
28 °C. MYD88 peptide inhibitor kit was dissolved in 1X sterile PBS. For inhibitors studies involving
29 incubations longer than 24 hours; inhibitors were replenished in culture media every 24 hours with
30 the same concentrations. Details of all the inhibitors used in this study are mentioned in table S3.

31 **Mammalian cell culture:** SIM-A9, COS-7 cells were obtained from American Type Culture
32 Conditions (ATCC). RAW 264.7 macrophages were kind gift from Dr. Christine A. Petersen,
33 Department of Epidemiology, College of Public Health, University of Iowa. J774A.1 were a kind
34 gift from Prof. Deborah Nelson, Department of Pharmacological and Physiological Sciences,
35 University of Chicago. HepG2 cells were kind gift from Dr. Bryan Dickinson, Department of
36 Chemistry, University of Chicago.

37 RAW 264.7, J774A.1, COS-7 and Hep G2 cells were cultured in Dulbecco's modified Eagles
38 medium/F12 (1:1) (DMEM-F12) with 10% FBS as per ATCC protocol. SIM-A9 was cultured in
39 DMEM-F12 with 10% Fetal Bovine Serum (FBS) with 5 % Horse serum (Invitrogen co-operation,
40 USA). DMEM Media were supplemented with 100 U/mL of penicillin, 100 µg/mL of streptomycin
41 (Life Technologies).

42 **Bone marrow-derived macrophage (BMDM) isolation and activation.** BMDMs were
43 differentiated from bone marrow stem cells with L-cell conditioned media for six days as
44 previously described(4). BMDMs were stimulated by LPS (5 ng/mL, Sigma) and INF γ (12 ng/mL,
45 R&D Systems) for 24 hrs to be activated to M1 BMDMs, or 20 ng/mL IL-4 for 48 hrs to M2
46 BMDMs.

47 **Adipose tissue-macrophages (ATM) isolation.** Adipose tissue was minced and digested with 1
48 mg/mL type I collagenase in 1% BSA/PBS at 37°C shaker at 160 rpm for 40 minutes. Cell pellet
49 was centrifuged, lysed with red blood cell lysis buffer, and passed through 40 µm filter. ATMs
50 were isolated using CD11b microbeads (Miltenyi Biotec) as previously described(4), and purity
51 was assessed by flow cytometry.

52 **Thioglycolate-elicited peritoneal macrophage (Pmac) isolation.** Pmac were isolated as
53 previously described(5). Briefly, Pmac were isolated by lavaging the peritoneal cavity with PBS
54 containing 2% endotoxin-free BSA 5 days after 4% thioglycolate injection (3 mL/mouse).

55 **Assembly and characterization of Tudor:** Equimolar ratios of A1 and A2 oligos were mixed
56 to final concentration of 20 µM in 20 mM sodium phosphate buffer, pH 7.2 containing 10 mM
57 KCl, 10 mM MgSO₄. Annealing was done by heating it to 90 °C for 5 mins followed by cooling
58 to RT over 3 hours at the rate of 5 °C/15 mins. This was equilibrated at 4 °C overnight before
59 use. *Tudor* was characterized by mobility shift assay in 12% native poly acrylamide gel
60 electrophoresis (PAGE) (refer Supplementary note. 1)(6, 7).

61 **Competition assays:**

62 **Ku70/80 mediated uptake assay:** RAW264.7 were pretreated with 60 equivalence of unlabeled
63 SA43 (aptamer against Ku70/80 heterodimer proteins) in Opti-MEMTM for 30 mins after which
64 cells were treated with 50 nM *Tudor* for 30 mins in Opti-MEMTM. Cells were washed and chased
65 for 1 hour in complete media (DMEM containing 10% FBS) containing unlabeled SA43. Cells
66 without SA43 were treated with only the Opti-MEMTM as pre-pulse after which cells were treated
67 with same concentrations of *Tudor* and chased as mentioned above. Imaging was performed as
68 described in methods section.

69 **Scavenger receptor mediated uptake assay:** RAW264.7 cells were pretreated with 60
70 equivalence of mBSA for 30 mins in Opti-MEMTM after which cells were treated with 100 nM
71 *Tudor* or dsDNA for 30 mins in Opti-MEMTM containing 60 equivalence of mBSA. Cells were
72 washed and chased for 1 hour in complete medium containing mBSA. Cells without mBSA were
73 pretreated with Opti-MEMTM alone followed by pulse and chase with *Tudor* or dsDNA devoid of
74 mBSA.

75 All analysis for uptake assays were performed using Fiji(8). To quantify uptake, images were
76 background subtracted, whole cell intensity for each cell were measured using cell outlines drawn
77 in the brightfield channel.

78 **Uptake of *Tudor*^{A647} assay:** Raw 264.7 macrophages were transfected with either 100 nM of
79 siRNA against Ku70 or scrambled siRNA using Mirus *TransIT*- TKO transfection reagent as per
80 manufacturer's manual. After 72 hours of transfection, RAW 264.7 macrophages were pulsed with
81 50 nM *Tudor*^{A647} for 30 mins in Opti-MEMTM. Cells were then washed and chased in complete
82 media at 37 °C for 1 hour and imaged by confocal microscopy. Analysis: Images were background
83 subtracted using Fiji. Whole cell intensity (WCI) was measured for each cell using Fiji.

84 **Lysosomal tubulation assay:** RAW 264.7, J774A.1, SIM-A9, Hep G2, COS-7 cells; murine
85 ATM; BMDM and Pmac were pulsed with 0.5 mg/ mL TMR dextran for 1 hour and chased in
86 complete media for 16 hours to specifically label lysosomal compartments. Cells were then treated
87 with 100 nM *Tudor* in culture media for 4 hours. Cells were imaged using either a widefield or
88 confocal microscope. LPS (100 ng/mL) was used as a positive control for lysosomal tubulation
89 assay where cells were incubated with LPS for 4 hours at 37 °C in culture media. For time
90 dependent tubulation assay, cells were treated with unlabeled 100 nM *Tudor*; 100 nM dsDNA or
91 100 ng/ mL LPS (t=0 mins) in complete media. Cells were imaged at different time points (0; 1;
92 2; 4; 8 and 12 hours) for the formation of tubular lysosomes.

93 **Fluorescence microscopy imaging:**

94 IX83 inverted wide field microscope (Olympus Corporation of the Americas) was used with 60x,
95 1.42 NA or 100X, 1.42 NA, differential interference contrast (DIC) objective (PLAPON, Olympus
96 Corporation of the Americas) and Evolve Delta 512 EMCCD camera (Photometrics). The
97 microscope, filter wheel, shutter, and charge-coupled device camera were controlled using
98 MetaMorph Premier Ver 7.8.12.0 (Molecular Devices LLC, USA). Alexa 488 was imaged with
99 500/20 band-pass excitation filter, 535/30 band-pass emission filter and 89016 dichroic mirror.
100 Atto 647N was imaged with 640/30 band-pass excitation filter and 705/72 band-pass emission
101 filter with 89016 dichroic. TMR dextran and pHrodoTM Red zymosan was imaged with 530/30
102 band pass excitation filter with 575/40 band pass emission filter and 49014 long pass dichroic
103 filter. Images in Alexa 488 channel were acquired with 300 ms exposure time and 300 EM Gain.
104 TMR dextran, pHrodoTM red and Atto 647N channel were acquired with 100 ms exposure and 100
105 ms EM Gain.

106

107 The confocal microscope used in the study is Leica TCS SP5 II STED laser scanning confocal
108 microscope (Leica Microsystems, Inc.) with an Argon ion laser for 488-nm excitation, DPS laser
109 for 564-nm excitation and an He-Ne laser for 594-nm, 633-nm excitation, using HCX PI Apo
110 63x/1.4 UV oil 0.14mm WD objective. ER TrackerTM Green, Mito TrackerTM Green, FITC
111 dextran, Alexa 488 dextran, DCF, Rhodamine 110 was excited with Argon laser at 488 nm; TMR
112 Dextran, pHrodoTM Red, Rhod5F was excited using DPSS laser at 561 nm; DQTM BSA Red was
113 excited with orange HeNe laser 594 nm. Lyso TrackerTM deep red, Alexa 647, Atto 647N was
114 excited using Red HeNe laser 633 nm. Acousto-optical beam splitter (AOBS) was used to filter all
115 emission signals with suitable settings for each fluorophore (Table S4). Images were recorded
116 using hybrid detectors (HyD). All images from both widefield, and confocal microscopes were
117 acquired sequentially.

118

119 Time lapse imaging: Time lapse imaging for RAW 264.7 with tubulated lysosomes labeled with
120 *CalipHluore 2.0* was imaged in Leica TCS SP5 II STED laser scanning confocal microscope with
121 63X, 1.4 NA objective in G, O and R channels. The images were acquired for upto 10 mins with

122 15 secs time intervals. Images were background subtracted, bleach corrected and processed to
123 construct pH and calcium (log) Images according to previously established procedure(9).

124
125 **Quantification of Tubular lysosomes:** Tubeness plugin from Fiji(8) was used to highlight any
126 curvilinear structures in the images(10, 11). The images were thresholded and Feret value of 0-10
127 was used to identify all structures between 0-10 μm in length and circularity of 0-0.5 for only
128 tubular structures and circularity of 0-1 is used to identify all tubular and vesicular lysosomes in
129 an image. *Analyze Particles* was used with above mentioned parameters to display the results of
130 area, feret length, intensity for all lysosomes analyzed. Lysosomes of Feret length $\geq 4.0 \mu\text{m}$ were
131 considered to be a TL(12).

132 After application of Tubeness filter, the image is thresholded. Thresholded image is used to further
133 analyze particles based on following parameters:

- 134 1. Feret Length (μm) which is defined as longest distance between two points in a region of
135 interest (ROI). Any lysosome with feret length of 4 μm is considered to be a tubular
136 lysosome.
- 137 2. Circularity: The range of circularity is chosen between 0 and 1. The circularity is calculated
138 based on the following equation:
139 $\text{Circularity} = 4\pi A/P^2$ where A = area; P=perimeter
140 Hence Vesicular lysosome: 1; tubular lysosome: 0

141 Below are the steps followed for image processing to identify and count tubular lysosomes:

- 142 1. Images are opened in Fiji and background subtracted.
- 143 2. Z-stack images with 15-18 slices of cells showing lysosomes labeled with 10 kDa
144 fluorophore containing dextran with z-steps size of 0.4 – 0.5 μm were acquired by confocal
145 microscopes. The size of z-stack will depend on the thickness of the cell. All images were
146 processed by Fiji, a free NIH image processing software (ref).
- 147 3. Once the image of interest is selected, the images are z-stacked with maximum intensity
148 projection (MIP).
- 149 4. Tubeness plugin is applied on z-stacked image. Default sigma value is applied to all images
150 to identify tubules of smaller diameter. “Use calibration information” box always remains
151 checked. This was performed using following operation: Plugins>Analyze>Tubeness.
- 152 5. The above image is thresholded using the following operation: Image>Adjust>Threshold.
153 Top and bottom sliders are adjusted to show all tubules and vesicular structures for the first
154 image. Similar thresholding parameters are applied to all images in that experiment.
- 155 6. Once these parameters are applied and image is thresholded, the pixel intensity values of
156 background becomes 0 and lysosomes within the cells become 255.
- 157 7. An ROI is drawn around the plasma membrane of that cell from its corresponding bright
158 field image and this ROI is then applied to the thresholded image.
- 159 8. “Convert to mask” is chosen when prompted for “converts the image into 8 bit mask or set
160 background pixel to NaN”.
- 161 9. This segmented image now is used to analyze both vesicular and tubular lysosomes using
162 the following: Analyze>Analyze particles.

- 163 10. Following parameters are used: Feret length (size in μm): 0-20 μm . This parameter depends
 164 on the length of the cell. In rare events, the tubular lysosomes run along the length of the
 165 cell. Circularity: 0-1 with 0 representing elongated rigid rod and 1 representing a circle.
 166 With display results checked in, all details of the ROI selected in the image will be
 167 displayed in a separate dialog box which includes Mean intensity, Area, Feret length etc.
 168 11. With “Show: Mask” chosen in Analyze particles will display the masked area in the cell.
 169 12. Based on Feret length, all lysosomes with length $\geq 4 \mu\text{m}$ are selected and counted as a
 170 tubular lysosome. All those lysosomes below $4 \mu\text{m}$ are considered to be vesicular
 171 lysosomes.
 172 13. Similarly, same parameters and applications are performed for other images in that
 173 experiment.

174 Analysis description:

175 (i) %TLs/cell: $\frac{\text{Number of TL}}{\text{Total number of lysosomes (VL+TL)}} \times 100$

176
 177 (ii) Tubulation quotient (%): $\frac{\text{Area occupied by TLs}}{\text{Area of all lysosomes (VL+TL)}} \times 100$ mean of n= 50-100 cells

178 We define this apparent “%Area of TLs” as “Tubulation quotient (%)”, which is a measure of the
 179 extent of tubulation. It is comparable with other analysis methods used in the literature to quantify
 180 tubulation efficiency with slightly more uniformity across cells within the same sample.
 181 “Tubulation Quotient” is analogous to the “signal gain” function for light microscopy. By this
 182 treatment, the area of one diffraction-limited $10 \mu\text{m}$ long TL is equivalent to that of 12-15 VLs.
 183 Experimentally, on average, a *Tudor*-treated cell contains 10 ($5 \mu\text{m}$) TLs per ~60-80 VLs (Fig
 184 S22), indicating that in a given cell, using Tubulation Quotient, TLs will account for ~50% of total
 185 lysosomal area. If we plug in the average dimensions from electron microscopy for these
 186 proportions, this would correspond to TLs occupying 25% of total lysosomal area. This gives an
 187 estimate of the gain function associated with the Tubulation Quotient.

188 **Colocalization experiments:** Lysosomes in RAW 264.7 were marked with TMR dextran as
 189 mentioned above. Cells were stimulated for tubulation of lysosomes with *Tudor* at 37°C . Cells
 190 were then loaded with either 200 nM Mito TrackerTM Green or 50 nM ER TrackerTM Green in
 191 HBSSA, incubated for 15-20 mins, washed in HBSS and then imaged in HBSS using Leica TCS
 192 SP5 II STED laser scanning confocal microscope.

193 **Inhibitor assay:** Lysosomes in RAW 264.7, BMDMs were pre-pulsed with TMR dextran as
 194 previously mentioned. Cells were then treated with specific inhibitors at 37°C followed by (100
 195 nM) *Tudor* for 4 hours at 37°C in the presence of the inhibitors. Cells were then imaged using a
 196 Leica TCS SP5 II STED laser scanning confocal microscope.
 197 Details of the concentration and incubation times of each inhibitor used are provided in Table S3.

198 **Induction of DNA damage:** Lysosomes in RAW 264.7 cells were labeled with 10kDA TMR
 199 dextran (0.5 mg/mL). Cells were treated with 50 and 200 μM of Etoposide for 1 hour or only the
 200 culture media at 37°C in standard culturing conditions. Cells were then either treated with
 201 unlabeled 100 nM *Tudor* or just the culture media in presence of Etoposide in above mentioned

202 concentrations for 4 and 8 hours. Cells were imaged in confocal microscope and scored for
203 tubulation of lysosomes at 4 and 8 hours.

204 **Specificity assays:** Equimolar ratios of MUC1-dsDNA; CpG-dsDNA; SA43 aptamer, dsDNA;
205 ssDNA and *Tudor* (refer to Table S1 and S2 for sequence and combinations of DNA used) were
206 annealed as per protocol discussed below at a final concentration of 10 μ M in 10 mM sodium
207 phosphate buffer, pH 7.2 containing 100 mM KCl and MgCl.

208 Lysosomes were marked by TMR dextran, Cells were then treated with (100 nM) MUC1-dsDNA;
209 CpG-dsDNA; SA43, ssDNA, dsDNA and *Tudor* for 4 hours at 37 °C. Cells were then imaged by
210 Leica TCS SP5 II STED laser scanning confocal microscope. Images were background subtracted.
211 Tubeness was used to analyze; Number of TLs; %TLs/Cells and Tubulation quotient (%) as
212 discussed above.

213 **siRNA gene silencing:** siRNA gene silencing in RAW 264.7 were performed using Trans IT-TKO
214 (Mirus Biol LLC) as per supplier's instructions. siRNA used was DsiRNA (IDT DNA, USA)
215 against mouse *Arl8b* (GENE ID: 67166). Two specific siRNA oligonucleotides were used against
216 *Arl8b* along with negative control from DsiRNA for transfection. Complete media was added 15
217 mins post addition of transfection mixture. Gene silencing was confirmed by quantitative real time
218 PCR for *Arl8b* after 72 hours of transfection. Lysosomal tubulation assay was performed after 72
219 hours of transfection using the above mentioned protocol.

220 **MMP9 activity assay:** RAW 264.7 cells were seeded at a density of ~100,000 cells per well in 96
221 well plate and grown with standard culturing conditions. MMP9 activity assay was performed as
222 per manufacturer's instructions in MMP9 activity assay (Anaspec). Briefly, media was replaced
223 with assay buffer (50 mM Tris, 10 mM CaCl₂, 150 mM NaCl, 0.05 % BrijW L23, pH 7.5)
224 containing either APMA (final concentration of 1 mM) for 2 hours; MMP9 inhibitor-I (100 μ M
225 for 1 hour) or 500 nM *Tudor* for 4 hours. This was followed by addition of 200 X final
226 concentration of peptide substrate diluted in assay buffer. The substrate containing solution was
227 incubated on cells for 24 hours. The reaction was stopped using stop solution provided in the kit.
228 (Relative fluorescence unit (RFU) was measured using Synergy™ Neo 2 Multi -Mode Microplate
229 Reader with Ex/Em at 480 /520 nm. Mean fluorescence unit (MFU) was calculated and plotted
230 where signal from the APMA containing wells were normalized to 1. Normalized percentage
231 activity where the MFU of background hydrolysis (BH) was subtracted from the other samples
232 (APMA, MMP9-i, dsDNA and *Tudor*) was set to 0 % and APMA to 100 %.

233 **MMP9 activity kinetics assay:** RAW 264.7 cells were seeded at a density of ~100,000 cells per
234 well in 8-well plates and grown with standard culturing conditions. Where indicated, the culture
235 media was replaced with DMEM with 1 μ M ZSTK474 (PI3K-i). After 1 hour at 37°C, cells were
236 washed with PBS and incubated with either DMEM, DMEM containing 500 nM annealed SA43,
237 which is the functional domain of *Tudor*, or DMEM containing 500 nM annealed SA43 and 1 μ M
238 ZSTK474. After the indicated amount of time (0, 1, 2, 4, or 8 hours), the cell culture media was
239 removed and centrifuged at 1,000xg for 10min at 4°C. The supernatant was removed and stored at
240 -80°C until further use.

241 MMP9 activity was quantified using the SensoLyte Plus 520 MMP9 Assay Kit (Anaspec) as per
242 manufacturer instructions. Briefly, 100 μ L of samples from above and blank controls were added
243 to individual wells of the 96-well microplate coated with monoclonal anti-human MMP9. The
244 plate was covered and incubated with shaking at room temperature for 1 hour. The wells were then

245 washed 4x with 200 μ L of the 1X wash buffer provided. Then, 100 μ L of MMP9 substrate in the
246 provided assay buffer was added to all wells, including the samples and blank controls. The plate
247 was covered and incubated in the dark for 2 hours before adding 100 μ L stop solution to each well
248 and measuring the fluorescence intensity at Ex/Em=490nm/520nm with a Synergy Neo 2 Multi-
249 Mode Microplate Reader.

250 The relative fluorescence unit (RFU) of each sample was calculated by subtracting the blank
251 control fluorescence from the sample fluorescence. The RFU at each time point was normalized
252 to the fluorescence at time $t=0$ (i.e., MMP9 activity at $t=0$) for each sample and is represented as
253 F/F_0 as a function of time.

254 **qRT-PCR:**

255 **Measurement of M1 and M2 markers gene expression in BMDM and Pmac:** Cell pellets
256 were lysed in RLT buffer and total RNA was isolated using the RNAeasy kit (Qiagen) with on-
257 the-column DNase digestion (Qiagen). RNA was converted to cDNA using reverse transcription
258 kit (Qiagen), and amplified using QuantiTect SYBR Green PCR Kits (Qiagen). The primers
259 were used were as follows (F=forward, R= reverse):

260	<i>18s</i>	F: GCCGCTAGAGGTGAAATTCTT;	R: CGTCTTCGAACCTCCGACT
261	<i>Tnfa</i>	F: CACCACGCTCTTCTGTCTACTG;	R: GCTACAGGCTTGTCACCTCGAA
262	<i>Ilb</i>	F: AACTCAACTGTGAAATGCCACC;	R: CATCAGGACAGCCCAGGTC
263	<i>Il12</i>	F: GGAGCACTCCCCATTCCTACT;	R: GAACGCACCTTTCTGGTTACAC
264	<i>Nos2</i>	F: GCTCCTCTTCCAAGGTGCTT;	R: TTCCATGCTAATGCCGAAAGG
265	<i>Arg1</i>	F: CTCCAAGCCAAAGTCCTTAGAG;	R: AGGAGCTGTATTAGGGACATC
266	<i>Il10</i>	F: GCTCTTACTGACTGGCATGAG;	R: CGCAGCTCTAGGAGCATGTG.
267	<i>Ym1</i>	F: GCCCACCAGGAAAGTACACA;	R: TGTTGTCCTTGAGCCACTGA.
268	<i>Cd11b</i>	F: CCATGACCTTCCAAGAGAATGC,	R: ACCGGCTTGTGCTGTAGTC.
269	<i>Ctb</i>	F: CTGCGCGGGTATTAGGAGT;	R: CAGGCAAGAAAGAAGGATCAAG
270	<i>Ctl</i>	F: AGACCGGCAAACCTGATCTCA;	R: ATCCACGAACCCTGTGTCAT
271	<i>Lamp1</i>	F: ACATCAGCCCAAATGACACA;	R: GGCTAGAGCTGGCATTTCATC
272	<i>Atp6vod2</i>	F: CAGAGCTGTACTTCAATGTGGAC;	R: AGGTCTCACACTGCACTAGGT
273			

274 **Gene expression measurements of key proteins in autophagy and Tudor mediated tubular**
275 **lysosome pathway in RAW 264.7 macrophages:** Cells were transfected with respective siRNA
276 using Mirus *TransIT*- TKO transfection reagent as per manufacturer's manual for 72 hours. Cells
277 were then lysed and RNA was isolated using Trizol (Thermo Scientific) as per manufacturer
278 protocol. RNA was converted into cDNA using SuperScriptTM III Reverse Transcriptase (Thermo
279 Scientific) as per manufacturer's protocol. cDNA obtained was amplified using QuantiTect SYBR
280 Green PCR Kits (Qiagen).

281 18S was used as internal control for all qRT-PCR experiments performed.

282 Primer sequences used in are mentioned below:

283	<i>Ulk1</i>	F: ACATCCGAGTCAAGATTGCTG,	R: GCTGGGACATAATGACCTCAGG
284	<i>Map1lc3b</i>	F: TTATAGAGCGATACAAGGGGGAG,	R: CGCCGTCTGATTATCTTGATGAG
285	<i>Ku 70</i>	F: AGAAGCACTTCCGAGACACG,	R: TCGTCTTCATTGGTGAACAGC

286 *PI3K* F: ACACCACGGTTTGGACTATGG, R: GGCTACAGTAGTGGGCTTGG
287 *mTOR* F: CAGTTCGCCAGTGGACTGAAG, R: GCTGGTCATAGAAGCGAGTAGAC
288 *Arl8b* F: TGGTTCCGTTTCGCTCTTCTG, R: GCGATGACATTGACGAAGGTG
289 *AMPK* F: GTCAAAGCCGACCCAATGATA, R: CGTACACGCAAATAATAGGGGTT
290 *LKB1* F: CTGGACTCCGAGACCTTATGC, R: CAAGCTGGATCACATTCCGAT

291 **RT PCR:** Total RNA was isolated using Trizol as per instructions by manufacturer (Invitrogen).
292 First strand synthesis was performed using Super Script III as per manufacturer's instructions
293 (Thermo Scientific). 10 μ L of PCR product was run on 2.0 % agarose gel in TAE buffer.

294 MMP9 and GAPDH specific primers used were as follows:

295 MMP9 F: CCTGTGTGTTCCCGTTCATCT, R: CGCTGGAATGATCTAAGCCCA
296 GAPDH F: CCCAGAAGACTGTGGATGG, R: CACATTGGGGGTAGGAACAC

297

298 **Western blot analyses:**

299 **Transcription factors:** M0 BMDMs were treated with either 100 nM *Tudor* or dsDNA for 24
300 hours in culture media. Cells were scraped and lysed with 1% SDS containing protease and
301 phosphatase inhibitors (Sigma), and protein was quantified with the BCA Protein Assay Kit
302 (Pierce). Proteins (10-20 μ g) were resolved on 10% SDS-PAGE gels, transferred to PVDF
303 membranes (Millipore), blocked with 5% BSA (Sigma) in 0.1% TBS/Tween-20 at RT for 2hrs,
304 stained with primary and secondary antibodies, and visualized using the ECL detection kit (Biorad)
305 and a LI-COR imager. Antibodies include: pSTAT1 (7649), tubulin (2125), pNF-kB (3033) are
306 from Cell Signaling Technologies.

307

308 **Proteins in the tubulation cascade:** RAW 264.7 macrophages were treated with inhibitors; Torin
309 1 (100 nM, 1 hour); dorsomorphin (20 μ M, 1 hour); Zstk474 (1 μ M, 30 mins), Akt inhibitor VIII
310 (5 μ M, 30 mins), LKB1 inhibitor (380 nM, 24 hour) in culture media. Cells were then treated with
311 either LPS (100 ng/mL) or *Tudor* (100 nM) in presence or absence of the respective inhibitor for
312 4 hours in culture media. Untreated (UT) cells were used as negative control.

313 Cells were lysed with 1% SDS in RIPA buffer containing protease inhibitor cocktail (Sigma).
314 Protein isolated were quantified with the BCA Protein Assay Kit (Thermo Scientific). Proteins
315 (20-30 μ g) were resolved on 10-12.5% SDS-PAGE gels, transferred to PVDF membranes
316 (Genesee Scientific), blocked with 5% BSA (Sigma) in 0.1% TBS/Tween-20 at RT for 1 hr, stained
317 with primary and secondary antibodies where primary and secondary antibodies were diluted in
318 1% BSA in TBST overnight at 4 $^{\circ}$ C in moist chamber. The blots were visualized using the
319 SuperSignalTM Western Blot enhancer kit (Thermo scientific) in Biorad ChemiDoc MP Molecular
320 imager. Antibodies used were: S6K(2217S,1:1000), p-S6K, (4858S, 1:1000), AMPK (2603S,
321 1:1000), p-AMPK (2535S, 1:1000), PI3K (4249T, 1:1000), p-PI3K (4228T, 1:1000), Akt (4685,
322 1:1000), p-Akt (4060, 1:1000), LKB1 (30475, 1:1000), p-LKB1 (34825, 1:1000), are from Cell
323 Signaling Technologies; tubulin (ab6160, 1:5000), Actin (ab14128, 1:5000) from abcam. All
324 respective secondary antibodies used were in 1:5000 diluted in antibody dilution buffer.

325

326 **Fixation protocols for TLs:**

327 **3% Glyoxal fixation:** Fixation protocol was modified from previously described method(13)
328 Briefly, for 4 mL of total fixative solution; 0.789 mL of absolute ethanol, 0.313 mL 40% glyoxal
329 and 0.03 mL acetic acid were added and the final volume was made up to 4 mL with 1X PBS. pH
330 was set to between 4 and 5 using NaOH. Fixative was prepared freshly just before the experiment.
331 Cells were treated with 3% glyoxal fixative for 20 mins at RT.

332 **1% Glyoxal Fixation:** Fixative was prepared similar to above mentioned method by just changing
333 the amount of 40% glyoxal solution added to 0.1 mL. Cells were treated with 1% glyoxal fixative
334 exactly for 5 mins at RT.

335 **0.5% PFA(v/v) +0.45% GA (v/v):** The final concentration 0.5 % PFA (Electron Microscopy
336 Sciences) + 0.45 % of GA (Sigma) and was prepared in 1X PBS. Cells were treated with 0.5 %
337 PFA + 0.45 % GA for 15 mins at RT as reported previously(14).

338 **2% PFA(v/v) + 0.2 % GA (v/v):** The final concentration 2% of PFA and 0.2 % GA was prepared
339 in 1X PBS. Cells were treated with 2 % PFA+ 0.2 % GA for 5 mins at RT.

340 Post fixation in the above-mentioned fixatives; cells were washed in 1X PBS and imaged.

341 **Immunofluorescence:**

342 **Plasma membrane labeling of Ku70:** RAW 264.7 cells were fixed with 2% PFA for 10 mins on
343 ice and gently washed 3 times with ice cold 1X PBS. Cells were blocked with 1% BSA and 0.3 M
344 Glycine in 1X PBS for 30 mins at RT. Cells were labeled with Ku70 in blocking buffer for 1 hour
345 in RT followed by 3 washes in 1X PBS. Cells were then stained with secondary antibody in
346 blocking buffer for 30 mins at RT. Cells were then blocked with 4% FBS+3% BSA in 1X PBS for
347 30 mins followed by Pan Cadherin antibody overnight incubation. Cells were incubated in
348 secondary antibody for 30 mins post washes. Cells were washed and imaged.

349 **Nrf2 labeling:** RAW 264.7 cells were treated either untreated or with Tert-butylhydroquinone
350 (tBHQ) (Sigma) (5 μ M) for 1 hour or 100 nM *Tudor* for 4 hours in culture media. Cells were fixed
351 in 4 % PFA in 1X PBS for 20 mins. Protocol used for immunofluorescence for Nrf2 was as per
352 previously published literature with minor changes(15). Briefly, cells were permeabilized in 0.2%
353 Triton X 100 for 10 mins, RT. Blocking was performed in 1X PBS containing 3% BSA+4% FBS
354 +0.2% saponin for 3 hours. Primary Nrf2 (1:100) antibody was incubated overnight at 4 °C in
355 blocking buffer followed by secondary antibody (1:1000) for 30 mins, RT in blocking buffer. Cells
356 were stained with Hoechst dye 10 mins before imaging.

357 **Cathepsins B labeling in VLs and TLs:** RAW 264.7 were treated with either 100 ng/ mL LPS,
358 100 nM *Tudor*, dsDNA or culture media (untreated) for 4 hours at 37 °C. Cells were fixed with
359 2% PFA, 0.2% GA in 1X PBS for 15 mins in room temperature followed by treatment with 0.1%
360 glycine and 3% BSA in 1X PBS for 5 mins, RT. Next, cells were permeabilized with 0.2%
361 Triton™ X100 for 5 mins in 1X PBS and blocked in 4% FBS and 3% BSA in 1X PBS for 2 hours
362 followed by incubation with primary Cathepsin B antibody in blocking buffer overnight at 4 °C in
363 a moist chamber. Cells were then treated with secondary antibody for 1 hour in RT. Again,
364 blocked-in blocking buffer for 2 hours followed by LAMP1 antibody for 1-hour, RT. The

365 secondary antibody was then added at RT for 30 mins. Between every step mentioned above cells
366 were thoroughly washed in PBST. Cells were then imaged.

367 **Plasma membrane labeling of Phosphatidylinositol (3,4,5) triphosphate:** Cells were treated
368 with 1 μ M ZSTK474 for 30 mins; 100 nM Torin 1 for 1 hour followed by 100 nM *Tudor* in
369 presence or absence of the inhibitor for 4 hours in culture media. Cells were then fixed in 5%
370 PFA+0.45% GA for 10 mins at RT and incubated in 100 mM Glycine and 1% BSA for 5 mins.
371 Permeabilization was performed using 0.2% saponin for 3 mins followed by blocking in 5% FBS
372 and 1% BSA for 1 hour. Cells were then incubated with PIP3 antibody for 1 hour at RT, followed
373 by secondary antibody for 30 mins, RT. Cells were blocked again with 4% FBS and 3% BSA for
374 30 mins prior to addition of Pan cadherin antibody overnight at 4° C. Cells were then incubated
375 with secondary antibody for 1 hour, RT, washed and imaged. Between every step mentioned above
376 cells were thoroughly washed in PBST.

377 Image acquisition for immunofluorescence: Cells were imaged in Leica TCS SP5 II STED laser
378 scanning confocal microscope. All images were processed using Fiji.

379 **DNA sensors preparation and characterization:**

380 **Measurement of extinction coefficient of 5(6)-Carboxy-2',7'-dichlorofluorescein (DCF):**
381 DCF was dissolved into dry DMSO to create a primary stock of 50 mM and was stored at -20
382 °C until used. Different dilutions of DCF were prepared in deionized water and absorption
383 spectra for each were measured using a UV spectrophotometer. Using Beer-Lambert's law,
384 extinction coefficient was estimated from different concentrations of DCF in deionized water
385 and found to be $90000 \text{ M}^{-1} \text{ cm}^{-1}$.

386 **Conjugation of DCF to DNA and *ImLy2.0* preparation:** DCF was modified with NHS ester
387 according to previous protocol(16). 20 μ M of the amine labeled 57 base strand (C1) was coupled
388 to DCF-NHS ester (40 eq.), in 20 mM sodium phosphate buffer pH 7.0 and stirred overnight at
389 RT. DCF conjugated DNA was purified by ethanol precipitation(17) and quantified using UV-
390 absorption spectroscopy by measuring absorbance at 260 nm for DNA and 504 nm for DCF. The
391 reaction mixture was purified by amicon ultra 0.5 mL centrifugal unit with filter MWCO 3kDa
392 followed by ethanol precipitation to remove any residual free dye. The ethanol precipitated
393 DNA conjugated to DCF was reconstituted in 20 mM Sodium phosphate buffer, pH 7.2. The
394 efficiency of conjugation of DNA to DCF was further confirmed by 20% denaturing PAGE.
395 Once DCF is conjugated to C1 DNA. Equimolar ratios of C1 (DCF containing DNA), C2 (Atto
396 647 dye containing DNA) and C3 (DBCO- modified DNA) was mixed to final concentration of
397 10 μ M and annealed in 10 mM Sodium phosphate buffer (pH 7.2). The formation of *ImLy 2.0*
398 was confirmed by 15% native PAGE.

399 ***In vitro* fluorescence measurements of *ImLy 2.0*:** *In vitro* calibration for *ImLy2.0* was performed
400 using Fluoromax spectrophotometer (Horiba Scientific) as reported earlier(18). Briefly, 30 nM of
401 *ImLy 2.0* was diluted in pH clamping buffer (CaCl₂ (50 μ M to 10 mM), HEPES (10 mM), MES
402 (10 mM), sodium acetate (10 mM), EGTA (10 mM), KCl (140 mM), NaCl (5 mM), and MgCl₂
403 (1 mM)) between pH 3.5 and pH 7.2 and allowed to equilibrate at RT for 30 mins. Fluorescence
404 spectra was collected for each sample for DCF (G) by exciting at 504 nm and collecting emission
405 spectra from 512nm to 560 nm and Alexa 647 (R) by exciting at 647 nm and collecting emission
406 spectra from 650 nm to 700 nm. The ratio of emission maxima of G and R which is 520nm:665

407 nm was measured. The normalized G/R values from three independent experiments were plotted
408 as a function of pH to generate *in vitro* calibration curve.

409
410 ***In cellulo* clamping of *ImLy 2.0*:** RAW 264.7 were labeled with 500 nM *ImLy 2.0* (DCF: in Opti-
411 MEM™ for 30 min followed by a chase of 30 mins in complete media. Cells were washed, fixed
412 in 4% PFA in 1X PBS for 20mins. After thorough washing, cells were clamped in clamping buffer
413 (120 mM potassium chloride, 5 mM sodium chloride, 1 mM magnesium chloride, 1 mM calcium
414 chloride, 20 mM HEPES, 20 mM MES, 20 mM sodium acetate) at various pH containing 50 μM
415 Nigericin and 50 μM Monensin for 1 hour at RT. Cells were imaged using a widefield microscope.
416 Image analysis: Images were background subtracted and thresholded which was used to obtain
417 ROIs for vesicular lysosomes. The ROIs were applied to background subtracted images of G and
418 R separately. The G values and R values were noted for each lysosome. G/R was plotted for each
419 pH point in each experiment.

420 ***In cellulo* pH measurements by *ImLy 2.0*:** RAW 264.7 pulsed with 500 nM *ImLy 2.0* for 30 mins
421 in Opti-MEM™ followed by chase in complete media for 30 mins. Cells were imaged by wide
422 field microscope in HBSS. Lysosomes in cells were tubulated with *Tudor* followed by incubation
423 with 500 nM *ImLy 2.0* in Opti-MEM™ and a chase of 30 mins in complete media. Cells were
424 washed and imaged in HBSS. Image analysis: Images were background subtracted. Tubeness, a
425 plugin in Fiji was used to highlight any tubular and vesicular structures in the R channel image.
426 The image was then thresholded which was used to obtain ROIs for vesicular and tubular
427 lysosomes. The ROIs were applied to background subtracted images of G and R separately. The
428 G values and R values were noted for each lysosome. G/R was plotted for each pH point in each
429 experiment.

430 ***CalipHluor 2.0* preparation:** 1 mM of Rhod-5F-Azide was conjugated to 10 μM DBCO-C3 in
431 100 μL of 20 mM sodium phosphate buffer pH 7.2 and stirred overnight at RT(9). The reaction
432 mixture was ethanol precipitated to remove any free dye. DNA conjugated to Rhod-5F was
433 reconstituted in 20 mM sodium phosphate buffer pH 7.2. Conjugation was confirmed by 12%
434 denaturing PAGE. *CalipHluor 2.0* was prepared by mixing eq molar concentrations of each
435 oligonucleotides (5 μM) containing DCF, Rhod5F and a ratiometric dye (Atto 647N) in
436 annealing buffer containing 100 mM KCl and 10 mM sodium phosphate buffer pH, 7.2. The
437 formation of *CalipHluor 2.0* was confirmed by gel mobility shift assay in 15% native PAGE.

438 ***In vitro* bead calcium calibration:** The protocol followed for *in vitro* calibration of *CalipHluor*
439 *2.0* is as per (9). Briefly, 500 nM of *CalipHluor 2.0* was incubated with 0.6 μm monodisperse
440 silica beads in 20 mM sodium phosphate buffer, pH 5.1 containing 500 mM NaCl for 30 mins at
441 RT. The beads were washed thrice by spinning at 10000 rpm for 10 mins each at room temperature.
442 Beads adsorbed with *CalipHluor 2.0* were incubated with clamping buffer (HEPES (10 mM), MES
443 (10 mM), sodium acetate (10 mM), EGTA (10 mM), KCl (140 mM), NaCl (500 mM), and MgCl₂
444 (1 mM)) for 30 mins, RT containing 0.1 μM or 10 mM free calcium buffers at pH (4.0, 4.6, 5.1,
445 6.0 and 7.2. The 2 μL of beads- *CalipHluor 2.0* solution was imaged on a glass slide in widefield
446 microscope. Rhod-5F(O), Atto 647N (R) and DCF (G) was excited at 545 nm, 647 nm and 504
447 nm respectively. O/R (calcium) and G/R (pH) from three independent experiments were plotted
448 for each calcium concentrations as function of pH from individual images.

449

450 ***In vitro* Calcium calibration:** 100 nM of *CalipHluor 2.0* was incubated in calcium clamping
451 buffer (HEPES (10 mM), MES (10 mM), sodium acetate (10 mM), EGTA (10 mM), KCl (140
452 mM), NaCl (5 mM), and MgCl₂ (1 mM)). 0.1 μM and 10 mM free calcium buffers were prepared
453 at pH (4.0, 4.6, 5.1, 6.0 and 7.2). Rhod-5F(O), Atto 647 (R) and DCF (G) was excited at 545 nm,
454 647 nm and 504 nm respectively. Emission spectra for Rhod-5F, Atto 647N and DCF was collected
455 from 570 nm to 620 nm, 650 to 700 nm and 512 to 560 nm respectively. Mean emission maxima
456 of O/R and G/R from three independent experiments were plotted for each calcium concentrations
457 as function of pH comparing with the *in vitro* bead calibration performed on widefield microscope.
458 Free calcium at given pH for both in vitro calibration was found using
459 <https://somapp.ucdmc.ucdavis.edu/pharmacology/bers/maxchelator/CaEGTA-NIST.htm>
460

461 ***In cellulo* pH and Calcium clamping:** *In cellulo* clamping for calcium was performed as
462 mentioned in(9). Cells were treated with 500 nM of *CalipHluor 2.0* for 30 mins followed by a
463 chase of 30 mins to make sure the *CalipHluor 2.0* has been targeted to lysosomes. Cells were then
464 fixed in 4% PFA for 20 mins, RT and washed. Cells were incubated in clamping buffer, pH 6.5
465 containing nigericin (50 μM), monensine (50 μM), ionomycin (20 μM) in clamping buffer
466 containing ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) (10 mM).
467 Cells were incubated with clamping buffer containing 10 mM free calcium for 1 hour, RT. Cells
468 were imaged using confocal microscope. Approximately over 500 endosomes were considered
469 from three independent experiments to compute mean G/R and O/R where G corresponds to mean
470 fluorescence intensity of DCF; O corresponds to Rhod-5F and R to Atto 647N. A pH calibration
471 curve was built using mean G/R from clamped lysosomes at pH 6.5 obtained from *CalipHluor 2.0*
472 and comparing the values with previous calibration curve from *ImLy 2.0*. This calibration curve
473 was used to measure the pH in real time using *CalipHluor 2.0*. O/R values were recorded and
474 considered to be O/R_{max} at pH 6.5.

475 **pH and calcium measurements:** Cells were either treated with 100 nM *Tudor* for 4 hours to
476 trigger tubulation of lysosomes or treated with 100 nM dsDNA. 500 nM *CalipHluor 2.0* was
477 pulsed and chased of 30 mins such that all lysosomes (TLs and VLs) are marked with
478 *CalipHluor 2.0*. Cells were imaged in confocal microscope. Quantification and calculation of
479 free calcium in lysosomes of RAW 264.7 were performed according to previously reported
480 method(9). For ammonium chloride treatment, lysosomes (VLs and TLs) were pulsed with
481 *CalipHluor 2.0* were chased for 20 mins in DMEM followed by 20 mins of chase in
482 Medium1(M1: 150 mM NaCl, 5 mM KCl, 1 mM CaCl₂, 1mM MgCl₂, 20 mM HEPES, pH 7.2)
483 buffer containing 10 mM Ammonium chloride at 37 °C. Cells were imaged in confocal
484 microscope in Opti-MEMTM or HBSS.

485 **Analysis of pH/Ca²⁺ gradient within TLs:** All TLs in a cell is considered for analysis except for
486 those which are parallel to the nucleus. All images were background subtracted. Tubeness plugin
487 in Fiji was used to highlight any tubular and vesicular structures in the R (Atto 647N) channel.
488 Images were then thresholded and used to obtain ROIs for VL and TLs. The ROIs were applied to
489 background subtracted images of G, O and R separately. G/R and O/R images were constructed
490 by dividing G channel image and O channel image with the R channel image. Nucleus was marked
491 with a ROI. A box of 5 X 5 pixels (length and breadth) ROI, which is the average size of a VL was
492 used to measure the G/R and O/R value along the TL starting from the side closest to the nucleus
493 and progressing towards the plasma membrane. The length of 5 X 5-pixel ROI was kept constant
494 throughout the analysis process although width varied based on the width of TLs. The mean

495 intensity of each box was noted as a function of length of the tubule in G, R and O channels and
496 were computed to obtain G/R and O/R values. G/R values were converted into pH using the
497 equation obtained from the pH calibration curve and O/R values were converted into free luminal
498 calcium concentration using equations established previously(9). Both pH and Calcium values
499 were normalized to its respective first value. Normalized pH and calcium values of each TLs were
500 fitted to a straight line to obtain a slope. TLs were segregated based on positive; negative or no
501 change (increase/decrease or no change) given by the slopes of pH and calcium values for each
502 TL. Therefore, TLs were segregated into population A, B or no gradient (n.g).

503 **Stability of *Tudor* in TLs:** Conjugation of A2-NH₂ to DBCO-PEG-ssDNA was performed as per
504 per previously reported literature(19). A2-PEG-DBCO was conjugated to azido-Alexa 488 using
505 click chemistry(20). Unconjugated azide containing Alexa 488 was removed and DNA was
506 concentrated by amicon ultra 0.5 mL centrifugal filters MWCO 3 kDa (Millipore Sigma).
507 Concentration of Alexa 488 conjugated oligo was measured by UV quantification. 10 μ M of Alexa
508 488 A2 DNA was annealed with Atto-647N labeled A1 in 10 mM potassium phosphate buffer,
509 100 mM KCl, pH 7.4. Annealing of dual labeled *Tudor* with Atto 647N and PEG-Alexa 488 was
510 performed as mentioned above. Lysosomes in RAW 264.7 were preloaded with 0.5 mg/ mL of
511 TMR dextran. Cells were then pretreated with 100 nM unlabeled *Tudor* for 4 hours for formation
512 of TLs. After 4 hours of incubation with unlabeled *Tudor*, cells were pulsed with 500 nM of dual
513 labeled *Tudor* containing Atto 647N (R) and PEG-Alexa 488(G) for 30 mins and chased over time.
514 Cells were imaged with time in wide field microscope. Image Analysis: Cells were background
515 subtracted. Tubeness from Fiji was used to highlight the tubular lysosomes. ROI generated by
516 analyze particles were used to obtain the G and R mean intensity values respectively. The G and
517 R values were plotted as a function of chase time.

518 **Stability of dsDNA in lysosomes of RAW 264.7 macrophages:** Conjugation of azide labeled
519 Alexa488 to DBCO-PEG-ssDNA (D1) was performed as reported previously. 10 μ M of Alexa
520 488 ss-DNA (D1) was annealed with 10 μ M of Atto 647N (D2) labeled DNA in 10 mM Potassium
521 phosphate buffer, 100 mM KCl, pH 7.4. Annealing of ds DNA was performed as mentioned above.
522 500 nM of dsDNA was pulsed for 30 mins in RAW 264.7 with lysosomes labeled with (0.5
523 mg/mL) TMR dextran and chased over time. Cells were imaged at different time points in wide
524 field microscope. Alexa 488 was considered as (G) and Atto 647N (R). Image Analysis: Images
525 were background subtracted. ROI was drawn around the whole cell and whole cell intensities were
526 plotted for both G and R as a function of chase time.

527 **Preparation of Alexa 488 conjugated dextran:** 2 mg of amino dextran (10 kDa) was mixed with
528 10 mM of Alexa488 carboxylic succinimidyl ester (Molecular Probes) in final concentration of 20
529 mM of sodium phosphate buffer, pH 7.2. The mixture was shaken in dark for approximately 8
530 hours. The excess dye was removed by amicon ultra 0.5 mL centrifugal filter with MWCO 3 kDa.
531 The final concentration and purity of conjugation was quantified by UV spectrophotometer.

532 **DQTM BSA assay:** The lysosomes in RAW 264.7 were labeled with Alexa 488 conjugated dextran
533 (3 kDa). Cells were treated with either *Tudor* or dsDNA in complete media and then pulsed with
534 DQTM-BSA red (10 μ g/ mL) for 10 mins in HBSS and chased for 30mins in HBSS such that DQTM
535 BSA is targeted to lysosomes. Cells were again washed and imaged using a confocal microscope.

536 **Conjugations of azido-Rhodamine110 to DBCO D1 DNA:** 30 μ M of DBCO containing D1
537 DNA was added to 5 equivalence of carboxy rhodamine110 azide in 10 mM sodium phosphate

538 buffer, pH 7.2. The reaction mixture was mixed overnight at RT in dark. Unconjugated dye was
539 removed by ethanol precipitation. Concentration and purity of conjugation was quantified by UV
540 spectrophotometer. Extent of conjugation was also confirmed by 15% denaturing native PAGE.
541 Similar protocol was used for conjugation of azide containing cathepsin C probe to DBCO
542 containing D1 DNA. Success and concentration of conjugation was checked by UV
543 spectrophotometer. Both DNA conjugated with Rhodamine 110 and Alexa 647N containing D2
544 were annealed as per protocol mentioned above with complementary D2 DNA containing Alexa
545 647N. Annealed DNA nanostructures (Cat_{ON}, Cat_C) were confirmed by 12% native PAGE.

546 **Cathepsin C activity assay:** Cells were pre-treated with either unlabeled 100 nM *Tudor* or dsDNA
547 for 4 hours in complete media. Cells were then labeled with either 500 nM Cat_C or Cat_{ON} in Opti-
548 MEM™ for 30 min followed by a chase of 30 mins at 37 °C in complete media. Cells were washed
549 and imaged in HBSS using a confocal microscope. Image analysis was performed as follows;
550 Images were background subtracted. Alexa 647 channel is considered to be red (R) (excitation
551 maxima λ_{\max} = 650 nm) and Rhodamine 110 as green (G) (excitation maxima λ_{\max} = 500 nm).
552 Cat_{OFF} measurement: cells were pretreated with 50 μ M of E64 inhibitor for 24 hours. Cells were
553 then treated with 500 nM of Cat_C in presence of 50 μ M of E64 for 30 mins. Cells were washes and
554 chased for 30 mins in complete media containing 50 μ M E64.

555 **Image analysis for enzyme activity:** Images were background subtracted. Tubeness plugin in Fiji
556 was used to highlight any tubular and vesicular structures in the R channel image. The image was
557 then thresholded which was used to obtain ROIs for vesicular and tubular lysosomes. The ROIs
558 were applied to background subtracted images of G and R separately. Mean G/R was plotted was
559 computed for each experiment in Cat_{off} (G/R_{min}), Cat_{ON} (G/R_{max}) and real time measurements of
560 activity of either Cat_C (G/R_{probe}) for vesicular and tubular lysosomes. % Response was calculated
561 using the following equation.

$$562 \quad \% \text{ Response} = (G/R_{\text{probe}} - G/R_{\text{min}}) / (G/R_{\text{max}} - G/R_{\text{min}}) \times 100$$

563 **Zymosan pHrodo conjugation:** 5 mg/mL zymosan was freshly dissolved in 10 mM sodium
564 phosphate buffer, pH 7.2 containing 0.2% tween 20 and sonicated for 1 min. 0.5 mg/mL of
565 zymosan was mixed with 100 nM of pHrodo™ Red succinimidyl ester in 10 mM sodium
566 phosphate buffer, pH 7.2 for 4 hours with continuous shaking. The conjugated zymosan was
567 centrifuged at 5000 rpm for 5 mins at RT and stored at 4 °C until used.


568 **Zymosan uptake assay:** ~80000-100000 RAW 264.7, BMDMs, Pmac were plated in coverslip
569 containing culture dishes. Cells were either treated with 100 nM *Tudor*, 100 nM dsDNA, 100
570 ng/mL LPS or only culture media (untreated) for 4 hours followed by addition of pHrodo™ Red
571 conjugated zymosan (t=0 min) (excitation maxima λ_{\max} = 560 nm). Cells were imaged post addition
572 of zymosan at 37° C over 1 hour using a widefield microscope.

573 **Imaging conditions for pHrodo™ Red conjugated zymosan and its uptake analysis:**
574 pHrodo™ red conjugated zymosan particles were incubated in universal buffer (UB) (CaCl₂ (1
575 mM), HEPES (20 mM), MES (20 mM), sodium acetate (20 mM), KCl (120 mM), NaCl (5 mM),
576 and MgCl₂ (1 mM)) at pH 5.0 for 5 mins. 0.5 μ L of this solution was then imaged on glass slide
577 to set up the appropriate imaging conditions. Multiple stage positions were set to image various
578 fields of cells. Zymosan was added (t=0 mins). Cells were then imaged using the above imaging
579 conditions with time intervals of 3 mins up to 60 mins. The images obtained from uptake assay

580 were z-projected with maximum intensity projection. The images were background subtracted in
581 each stack. Each z-stacked image from time t=0 mins upto 60 mins were further stacked together
582 to form a time lapse showing internalizing of zymosan into phagosomes. Number of pHrodo™
583 Red zymosan particles uptaken into cells were counted with time.


584 **Zymosan uptake in presence of inhibitors:** RAW 264.7 were cells were treated with PI3K
585 inhibitor (1 μM, Zstk474, 30 mins); mTOR1/2 inhibitor (100 nM Torin1, 1 hour); MMP9 inhibitor
586 (100 μM, MMP9-I, 1 hour) or siRNA against *Arl8b* for 72 hours. Cells were then treated with 100
587 nM *Tudor* for 4 hours in presence or absence of inhibitor, scrambled or siRNA against *Arl8b*. Cells
588 were then pulsed with pHrodo™ Red conjugated zymosan for 30 mins at 37 °C. Cells were imaged
589 to score for internalized zymosan. Zymosan uptake was analyzed for ~100 cells in each condition.

590 **Phagosome lysosome fusion assay:** Cells were treated with 2 mg/mL, 10 kDa Alexa 488
591 conjugated dextran with 1 hour of pulse and chased overnight to mark all lysosomes. Cells were
592 then either treated with *Tudor*, dsDNA or only culture media (untreated) followed by the addition
593 of 0.5 μL pHrodo™ Red conjugated zymosan for 30 mins at 37 °C and imaged by confocal
594 microscopy. Imaging conditions before each experiment were set as mentioned above. Image
595 Analysis: All images were background subtracted. Alexa 488 dextran was considered to be green
596 (G) and pHrodo™ Red was considered to be red (R) and the fusion of phagosome to lysosome was
597 analyzed in single plane confocal images where the ROI was drawn in the R channel using Fiji.
598 The same ROI was used to obtain intensity values of both G and R channels and ratios were plotted
599 for fusion. For phagosome lysosome contacts analysis; The number of TLs making contact with a
600 single phagosome out of total Alexa 488 dextran containing TLs in a cell were counted.




601
602 **Figure S1: Characterization of *Tudor*.** (a, b) Gel mobility shift assay characterizing the assembly
603 of *Tudor* using 10% Native PAGE. Imaged in A647 (red) and EtBr (black) channels. Lane 1
604 showing the mobility of A2; Lane 2: A1 and Lane 3: equimolar A1 and A2 annealed product as
605 indicated in the schematic of *Tudor* as shown in (c).

606 **Supplementary Note 1: Characterization of *Tudor* by Native PAGE.** The formation of *Tudor*
 607 was confirmed by gel mobility shift assay with Native Polyacrylamide gel electrophoresis (PAGE)
 608 (Fig S1 a, b). *Tudor* consists of two single stranded oligonucleotides, namely, A2 strand: cyan
 609 strand containing Alexa 647 dye and A1 strand: orange strand contains the aptamer, SA43 which
 610 binds to Ku70/80 heterodimer on the cell surface followed by a trimer linker into (A3) sequence
 611 complementary to A2 (Fig S1c). A1 and A2 oligonucleotides and *Tudor* were stained with EtBr
 612 and imaged in both A647 and EtBr channels. A1 showed lower mobility shift compared to A2 in
 613 both A647 and EtBr channels while *Tudor* showed higher mobility shift compared to A1 and A2
 614 strands.




615
 616 **Figure S2: Ku70 mediates internalization of *Tudor* into the macrophages.** (a) Representative
 617 confocal images of *Tudor*^{A647} uptake in RAW 264.7 macrophages in presence of either scrambled
 618 siRNA or against *Ku70*. *Represents untransfected cell showing the uptake of *Tudor*^{A647}. Scale
 619 bar: 10 μ m. (b) Quantitative RT-PCR showing efficient knockdown *Ku70* normalized to
 620 expression levels of 18S rRNA (negative control, (NC)).



621
 622
 16

623 **Figure S3: Ku70 localizes on the plasma membrane of various cell lines and primary**
 624 **macrophages. (a-f)** Representative images showing colocalization of Ku70 (green) with Pan
 625 Cadherin (E-11, red) in (a) J774A.1; (b) SIM-A9; (c) Hep G2; (d) COS-7; (e) naïve (M0),
 626 LPS/INF γ activated- (M1), or IL4-activated (M2) BMDM and (f) naïve (M0), LPS/INF γ activated-
 627 (M1), or IL4-activated (M2) Pmac, Scale bar = 10 μ m. (g, h) Normalized intensity ratio of
 628 Ku70/Pan Cadherin for each indicated cell types. Data represents three independent experiments
 629 shown here (n=50 cells).

630 **Supplementary Note 2. Plasma membrane localization of Ku70 protein in different cell types:**
 631 Ku70/Ku80 heterodimers which is a DNA repair protein, performs nonhomologous end joining
 632 (NHEJ) in nucleus and are also found at the plasma membrane in certain cancer and immune
 633 cells(21–24). DNA aptamer SA43 was raised against the Ku70/Ku80 heterodimers present on the
 634 plasma membrane(25). The presence of Ku70 protein on the surface of plasma membrane was
 635 confirmed by immunofluorescence without permeabilization in various cell lines mentioned above
 636 (Fig S3).




637
 638 **Figure S4: Tudor specifically mediates tubulation of lysosomes.** Representative colocalization
 639 images of TMR-dextran labeled tubular lysosomes (red) with indicated organelle markers [green;
 640 (ER) – ER TrackerTM; Mitochondria (Mito)-MitoTrackerTM green; Lysosomes (Lyso) –
 641 LysoTrackerTM] in *Tudor* treated RAW 264.7 (a-c) and BMDM (d, e). All independent
 642 experiments were repeated at least three times. Scale bar = 10 μ m.

643
 644
 645
 646
 647

648

649



650

651 **Figure S5: Lysosomal tubulation is specifically triggered by *Tudor*.** (a and b) Schematic
 652 showing MUC1-dsDNA made of 5-TRG2 linked to A2 DNA complementary to A3 and CpG-
 653 dsDNA where CpG strand is linked to A2 DNA complementary to A3. (c) Representative confocal
 654 images of RAW 264.7 in presence of MUC1-dsDNA, CpG-dsDNA, SA43 aptamer and *Tudor*.
 655 Scale bar: 10 μm, inset scale bar: 4 μm. (d) Plot showing the Number of TLs in presence of
 656 indicated ligands. Error bars represent s.e.m from 3 independent experiments, (n= 20 cells per
 657 experiment); ***P< 0.0005; **P< 0.005 (one-way ANOVA with Tukey *post hoc* test). n.s: non-
 658 significant.


659 **Supplementary note 3: SA43 aptamer trigger tubulation of lysosomes.**

660 MUC1-dsDNA which was adopted from the prior art(26) incorporates 5-TRG2, a DNA aptamer
 661 which binds to hypo-glycosylated MUC-1 protein (Kd: 18 nM) upregulated on the plasma
 662 membrane of certain cancer cells(27). CpG-ODN, a TLR-9 ligand, can trigger innate immune
 663 response in mammalian cells(28). Briefly, 5-TRG2 aptamer is fused to 24mer DNA (A2) through
 664 a short tri-mer oligonucleotide linker. 5-TRG2 fused to A2 strand along with its complementary
 665 A3 strand forms MUC1-dsDNA. CpG-dsDNA was also adopted from prior work(29) where CpG
 666 strand is also linked through short tri-mer linker to 24mer (A2) oligonucleotide which is
 667 complementary to A3 strand forming CpG-dsDNA. CpG-dsDNA is visualized by Alexa 647N
 668 present on A2 strand while MUC1-dsDNA was visualized by Alexa 647N present internally on
 669 A2 strand. *Tudor*, MUC1-dsDNA and CpG-dsDNA have similar design which involves a single
 670 strand overhang followed by a dsDNA module whose length and sequence are similar. To confirm
 671 the specificity of *Tudor* in triggering tubular lysosomes we treated RAW264.7 with 100 nM of
 672 MUC1-dsDNA, CpG-dsDNA, SA43 aptamer and *Tudor* for 4 hours. SA43 and *Tudor* treated cells
 673 showed lysosomes predominantly tubulated compared to MUC1-dsDNA and CpG-dsDNA treated
 674 cells suggesting that it's SA43 aptamer which is internalized by Ku70/80 on the plasma membrane
 675 of the macrophages to trigger tubular lysosome formation.

676

677


678



679

680 **Figure S6: DNA damage does not prevent lysosomal tubulation.** (a) Representative
 681 images of lysosomes labeled with TMR dextran (10 kDa) in RAW 264.7 macrophages
 682 either untreated (UT) or treated with *Tudor* in the presence or absence of Etoposide (50
 683 or 200 μM) for 4 and 8 hours. Zoomed images of white box is shown below. (b)
 684 Quantification of number of TLs for the data in (a). Error bars represent standard error
 685 of mean from three independent experiments with $n \geq 15$ cells for each experiment. Scale
 686 bar: 10 μm; inset scale bar: 4 μm.

687




688

689 **Figure S7: *Tudor* triggers tubulation of lysosomes in various cell types.** (a) Representative
 690 fluorescence images of TMR dextran labeled lysosomes in *Tudor* treated SIM-A9, J774 A.1, COS-
 691 7 and Hep G2 cells. Scale bar: 10 μm; inset scale bar: 4 μm. (b) Quantification of the number of
 692 TLs on indicated cell types in presence of dsDNA, LPS or *Tudor* Error bars represent s.e.m from
 693 3 independent experiments, $n= 20$ cells per experiment; *** $P < 0.0005$; ** $P < 0.005$ (one-way
 694 ANOVA with Tukey *post hoc* test). n.s: non-significant.

695


696

697



698

699 **Figure. S8: *Tudor* tubulates lysosomes in murine primary macrophages.** (a) Representative
700 confocal images of TMR dextran labeled lysosomes in BMDMs, (b) Pmacs and (c) ATMs upon
701 treatment with dsDNA, LPS or *Tudor*. Inset magnified image of section shown in the white box
702 with * representing VLs and # representing TLs. Scale bar: 10 μ m, inset scale bar: 4 μ m. (d)
703 Number of TLs for M1 and M2 macrophages of BMDM and Pmacs (n = 20 cells), Errors are s.e.m
704 from 3 independent experiments from n= 50 cells.



705


706

707 **Figure S9: Image analysis framework for quantification of tubular lysosomes.** (i) Fluorescent
708 images of *Tudor* treated cells were background subtracted. (ii) the image was subjected to
709 Tubeness filter which highlights all curvilinear structures. (iii) image in (ii) was then converted
710 into a binary image by thresholding (0, 255). (iv) image in (iii) was used to find all structures (VLs

711 and TLs) using analyze particles in Fiji based on two parameters: Feret values (0-10) and
 712 circularity (range:0.0-0.5). (v) Tubular structures only $\geq 4 \mu\text{m}$ considered for statistical analysis
 713 and quantification. (vi) The data obtained taken for analysis by multiple methods, shown in **Figure**
 714 **S10**.

715

716



717

718 **Figure S10: Kinetics of lysosomes tubulation represented using various analysis methods.**

719 Kinetics of tubulation induced by LPS and *Tudor* mediated represented as (a) lysosomal tubulation


720 index⁽¹²⁾, (b) number of tubular lysosomes/cell⁽³⁰⁾ and (c) percentage of cells with tubular

721 lysosomes⁽³¹⁾ (d) the Number of TLs. Errors are standard error of mean of n = 50 cells.

722

723

724




725

726 **Figure. S11: mRNA expression profiles of Tudor or dsDNA treated Pmac (M0).** (a, b and c)
 727 Expression levels of M1 (a) and M2 (b) and macrophage marker (c) genes shown in Pmac (M0)
 728 upon dsDNA and Tudor treatment. All error bars represent s.e.m from three independent
 729 experiments.

730

731




732

733 **Figure S12: Autophagy is unaffected during *Tudor*-mediated tubulation of lysosomes.** (a)
 734 Representative images of RAW 264.7 macrophages with TMR dextran-labeled lysosomes treated
 735 with *Tudor* with the indicated proteins knocked down by siRNA. Zoomed images of white box
 736 shown below. (b) Number of TLs were plotted from (a). (c) qRT PCR showing the knockdown of
 737 autophagy genes (LC3 and ULK1) by siRNA. 18S rRNA was used as negative control (NC) and
 738 for normalization. Error bars in (b and c) represent standard error of mean (d) Immunofluorescence
 739 for Nrf2 shown in red in RAW 264.7 with untreated (UT); Nrf2 activator, tBHQ (5 μ M, 1 h) or
 740 *Tudor* treatments. Nuclear stain, Hoechst is shown in blue. (e) Ratio of the mean fluorescence
 741 intensities of Nrf2 in the nucleus to cytoplasm. (f) Western blot of p62 levels in whole cell lysates
 742 of RAW 264.7 either untreated (UT) or treated with LPS; *Tudor* or Rapamycin (Rapa). Actin is
 743 used as loading control. N=15 cells in each experiment. n.s: non-significant, (one-way ANOVA
 744 with Tukey post hoc test). Data from three independent experiments. Error bars represent standard
 745 deviation. (n=15 cells). Scale bar: 10 μ m; inset scale bars: 4 μ m.

746 **Supplementary Note 4: Autophagy is unaffected during *Tudor*-mediated tubulation of**
 747 **lysosomes.:** As TLs are also observed when the cell undergoes autophagy we wanted to check if


748 *Tudor* mediated tubulation was autophagy-related. Knocking down LC3 and ULK1 did not alter
 749 *Tudor* mediated tubulation of lysosomes (Figure S12a-c). The crosstalk between Nrf2 and
 750 autophagy via p62, the autophagy adaptor, is known(32–36) . We found that *Tudor* treatment did
 751 activate Nrf2 as seen in autophagy (Figure S12 d-e). These results together demonstrate that
 752 autophagy is unaffected during *Tudor* mediated tubulation of lysosomes.



754


755 **Figure. S13: Pharmacological perturbations in *Tudor* or LPS treated RAW 264.7 cells.** (a-c)
 756 Representative confocal images of TMR dextran labeled lysosomes in *Tudor* or LPS treated cells
 757 in the presence of indicated pharmacological inhibitors. Scale bar: 10 μ m, inset scale bar: 4 μ m.
 758 (d) Number of TLs per cell for (b-c), (n=20 cells), (Veh=DMSO). (e) Normalized activity of
 759 MMP9 in RAW 264.7 upon treatment with *Tudor* (in absence or presence of MMP9 inhibitor-1)
 760 and dsDNA where mean fluorescence unit of *Tudor* was normalized to maxima (100%). AF
 761 represents autofluorescence of cells without any treatment. *** $P < 0.0005$; (one-way ANOVA with
 762 Tukey *post hoc* test). Error bars represent s.e.m from three independent experiments.

763
 764




765
 766 **Figure S14: Inhibiting endocytosis does not prevent lysosomal tubulation induced**
 767 **by *Tudor*.** (a) Representative images of lysosomes labeled with TMR dextran (10 kDa)
 768 in RAW 264.7 macrophages treated with 100 nM *Tudor* in the presence or absence of
 769 Dynasore (50 μ M) for 4 h. White boxed regions are zoomed below. (b) Number of TLs
 770 per cell shown for (a). Error bars represent standard error of mean from three
 771 independent experiments with $n \geq 15$ cells for each experiment. Scale bar: 10 μ m;
 772 inset scale bar: 4 μ m. n.s: nonsignificant (one-way ANOVA with Tukey *post hoc* test).

773
 774



775


776 **Figure S15: RNAi knockdown demonstrates the involvement of the indicated**
 777 **players in the tubulation cascade induced by *Tudor*.** (a) Representative images of
 778 RAW 264.7 macrophages showing 10 kDa TMR dextran labeled lysosomes upon
 779 treatment with *Tudor* in presence or absence of siRNA against mentioned proteins.
 780 Zoomed images of white box shown below. Scale bar: 10 μ m; inset scale bars: 4 μ m. (b)
 781 Number of TLs per cell in the treatments described in (a). Error bars represent SEM
 782 (standard error of mean) from three independent experiments, (N=15 cells). (c) qRT-
 783 PCR levels demonstrating siRNA knockdown of the target genes. Scale bar: 10 μ m.
 784



785

786 **Figure S16: Lysosome tubulation cascade triggered by *Tudor* is conserved in BMDMs.** (a-c)
 787 Representative confocal images of TMR-dextran-labeled lysosomes of murine BMDMs treated
 788 either with *Tudor* or LPS where the indicated proteins are pharmacologically inhibited. (d) Number
 789 of TLs per cell for M1 (left) and M2 (right) obtained from (b and c). *** $P < 0.0005$; ** $P < 0.005$;
 790 * $P < 0.05$ (one-way ANOVA with Tukey *post hoc* test). Veh=DMSO; n.s: non-significant. Error
 791 represents s.e.m from three independent experiments with $n = 20$ cells per experiment. Scale bar:
 792 10 μm , Inset scale bars: 4 μm .

793
 794



795
 796 **Figure S17: *Tudor* treatment activated PI3K, Akt, mTOR, AMPK and LKB1.**
 797 Western blots showing activation (a) mTOR by S6K phosphorylation; (b) PI3K; (c) Akt;
 798 (d) AMPK and (e) LKB1 in total cell lysate from RAW 264.7 macrophages upon
 799 untreated (UT), LPS and *Tudor* treatment in presence or absence of respective inhibitors.
 800 Tubulin and Actin are used as loading controls. Blots shown here are representative of
 801 three independent experiments.





Figure. S18: Differential proteolysis in vesicular and tubular lysosomes of RAW 264.7 cells. (a) Representative confocal images of Alexa 488 dextran-labeled lysosomes (G) in RAW 264.7 cells treated with dsDNA, *Tudor* or LPS followed by 10 μg/mL of DQ™ BSA Red (R). Scale bar: 10 μm. (b) Insets show magnified regions indicated * represents VLs and # represents TLs. Scale bar: 10 μm and inset scale bar: 4 μm.

820




821

822

823 **Figure. S19: Cathepsin C activity in RAW 264.7 and BMDMs.** Representative confocal images
 824 of lysosomes in (a) dsDNA; (b) *Tudor* or (c) LPS treated RAW 264.7 cells labeled with CTC
 825 sensors (CatON Catc and CatOFF) with or without E64. CTC activity measurement in dsDNA or
 826 *Tudor* treated BMDM (d, e) for M0; (f, g) for M1 and (i, j) for M2 macrophages. Inset shown in

827 white box with * representing VLs and # represent TLs. (h, k) Quantification of % response of
 828 CTC in VLs and TLs upon treatment with dsDNA and *Tudor* in M1 and M2 BMDM respectively.
 829 All data obtained from three independent experiments with error representing s.e.m (n = 50 cells,
 830 m= 500 endosomes). ***P< 0.0005 (one-way ANOVA with Tukey *post hoc* test), n.s: non-
 831 significant. Scale bar: 10 μ m. Inset scale bar: 4 μ m.

832 **Supplementary Note 5: Cathepsin C (CTC) enzyme activity in VLs and TLs.** DQTM BSA
 833 degradation assay revealed the overall enzyme activity within tubular lysosomes is lower as
 834 compared to vesicular lysosomes (Fig 3a-c). Previous literature shows that in autophagy,
 835 stimulated tubules lacked cathepsins and acid phosphatase(37). Yet immunofluorescence of
 836 cathepsin B showed equal levels of staining in VLs and TLs of *Tudor* and LPS stimulated RAW
 837 264.7 (Fig S14c). We thus choose to study the enzymatic activity of CTC, one of the abundant
 838 lysosomal cysteine cathepsins. We used previously described DNA based CTC sensor (Catc) in
 839 this study(6) which consists of 2 modules namely, (i) sensing module made of azido Rhodamine
 840 110 which is caged by a CTC cleavage motif, Gly-Phe dipeptides and a (ii) ratiometric module
 841 comprising of Alexa 647N (denoted as R) which is insensitive to any perturbations during this
 842 process (Fig 3e).




843 **Figure. S20: Time dependent colocalization of dsDNA with lysosomes in BMDM.**
 844 Representative confocal images of TMR dextran labeled lysosomes colocalized with dsDNA-
 845 A647 at different chase times of 10 mins; 30 mins and 60 mins in M0 (a); M1 (c) or M2 (e)
 846 BMDMs. Pearson's correlation coefficient (PCC) and pixel shift measured at each indicated chase
 847 time for M0 (b); M1 (d) and M2 (f). Images and data represented from three independent
 848 experiments and error bars represent s.e.m (n = 12 cells per experiment). ***P< 0.0005 (one-way
 849 ANOVA with Tukey *post hoc* test), n.s: non-significant. Scale bar: 10 μ m. Inset scale bar: 4 μ m.

851 Lysosomal CTC cleaves the N-terminus of Gly-Phe dipeptide and renders Rhodamine 110 free
 852 which allows it to fluoresce (denoted as G). DNA based Cathepsin C ON probe (Cat_{ON}) which
 853 consist of azido-Rhodamine 110 denoted as G, and Alexa 647N as R (Fig 3e). Cat_{ON} sensor


854 provides the measure of the maximum cleavage based fluorescence signal and hence provide the
 855 maximum G/R ratio. Catc in presence of E64 (pan cathepsin inhibitor) shows the lowest or basal
 856 cleavage of Catc sensor and therefore provides minimum G/R ratio. % Response of CTC activity
 857 within the VLs and TLs upon different treatments were calculated as described in Methods section
 858 with single lysosomal resolution.

859



860


861 **Figure. S21: Fixation protocol for tubular lysosomes.** (a) Representative confocal images of
 862 TMR dextran labeled lysosomes in RAW 264.7 cells either untreated (no fixation and AF) or fixed
 863 using various mentioned fixatives (P1-P4). Insets show magnified regions indicated. Describe
 864 bottom table, either use a new panel # or describe as upper and bottom. (b) Number of TLs per cell
 865 of cells treated with various fixative compositions and un-fixed cells (n = 20 cells). ****P < 0.0005
 866 (one-way ANOVA with Tukey *post hoc* test), n.s: non-significant. (c) Mean G/R plot showing
 867 fluorescence intensity from immunofluorescence of Cathepsin B (G) and LAMP1 (R) in presence
 868 of dsDNA, *Tudor* and LPS (n=15 cells) in RAW 264.7. Errors represents s.e.m from three
 869 independent experiments. AF: Autofluorescence. Scale bar: 10 μ m, with inset scale bar: 4 μ m.



870

871 **Figure S22: Distribution of VLs and TLs in *Tudor*-treated RAW 264.7 macrophages.** (a) Total
 872 number of lysosomes per cell upon treatment with dsDNA, LPS or *Tudor*. (b) Size distribution of
 873 lysosomes based on their Feret length in these treatments. Lysosomes with Feret length > 4 μm
 874 are considered tubular. (c) Data in (c) represented as a violin plot showing the percentage of tubular
 875 lysosomes per cell across 50 cells. (d) Average number of vesicular lysosomes (VLs) and tubular
 876 lysosomes (TLs) per cell (n=50 cells). Error bars represent standard error of mean.

877 **Supplementary note 6: No change in number of lysosomes in tubular lysosome and vesicular**
 878 **lysosome containing cells.** How the lysosomal mass gets distributed between tubular (TL) and
 879 vesicular (VL) forms when tubulation is induced is still not well understood. It is still unclear even
 880 whether cells maintain the same number of lysosomes upon inducing tubulation. We therefore
 881 studied how the number and morphologies of lysosomes changed when cells were treated with
 882 *Tudor*. We analyzed the total numbers of VLs and TLs per cell (Fig. S22a); feret length (Fig.
 883 S22b); percentage of TLs per cell (Fig. S22c) and average number of VLs and TLs per cell (Fig.
 884 S22d) when they were treated with dsDNA, *Tudor* and LPS respectively. Our analysis revealed no
 885 perceptible differences in number of VLS in *Tudor*-treated or dsDNA-treated cells. However, we
 886 noticed that the fraction of TLs consistently increases upon treatment with either *Tudor* or LPS.




887

888

889 **Figure. S23: Characterization of *Caliphluor 2.0*:** (a) Schematic of ratiometric fluorescent pH
 890 corrected Ca^{2+} reporter, *Caliphluor 2.0*. It consists of Ca^{2+} sensitive dye, Rhod-5F (orange
 891 triangle); pH sensing dye, DCF (green circle) and ratiometric dye, Atto 647N (red star). (b)
 892 Denaturing PAGE (15%) showing the conjugation of Rhod-5F to DBCO containing D3 oligo in
 893 EtBr and TMR channels. (c) Native PAGE (15%) showing gel mobility shift of *Caliphluor 2.0* in
 894 Alexa 488, TMR and Alexa 647 channels. (d) Comparison of *in vitro* (purple) and on beads (pink)
 895 fold change of O/R ($\text{FC}_{\text{O/R}}$) ratios of *Caliphluor 2.0* from pH 4.0 - 7.2 ($n = 100$ beads).

896




897

898 **Figure. S24: Characterization of *ImLy 2.0*.** (a) Schematic of *ImLy 2.0* showing 5(6)-Carboxy-
 899 2',7'-dichlorofluorescein (DCF) on 58 mer (C1) oligo (green), Atto 647N (red) on the
 900 complimentary 28mer oligo (C2) and unlabeled 30mer oligo (C3). (b) Denaturing PAGE (15%)
 901 showing the conjugation of DCF to amine containing C1 in EtBr and Alexa 488 channels. (c) Gel
 902 mobility shift assay showing the formation of *ImLy 2.0* by 15% native PAGE imaged in EtBr,
 903 Alexa 647 and Alexa 488 channels. (d) Emission spectra of *ImLy 2.0* at pH ranging from 3.5 and
 904 7.0. (e) Representative images of RAW 264.7 showing the uptake of *ImLy 2.0* and pixel wise
 905 pseudocoloured images of G/R clamped at indicated pH. Inset showing the zoomed in area shown
 906 in the white box. Scale bar: 10 μ m. (f) Histogram of G/R ratios of lysosomes clamped at indicated
 907 pH ($n = \geq 90$ cells, $m = \geq 500$ lysosomes). (g) pH calibration (*in vitro*) for *ImLy 2.0* showing
 908 normalized G/R ratios versus indicated pH values. Error bars represents s.e.m from three
 909 independent experiments.

910 **Supplementary note 7: Calibration and lysosomal pH measurement using *ImLy 2.0*:**

911 Previously reported DNA based pH sensor, *ImLy* senses pH reliably between pH 3.8 and pH
 912 5.2(18). In order to probe pH between pH 4 and pH 6, we designed a new pH sensor *ImLy2.0*
 913 which is ideal for endo-lysosomal pH measurements. *ImLy2.0* comprises of 3 DNA strands, D1,
 914 58 mer DNA strand consists of amino modification on 5' end which is used for conjugation with
 915 DCF (the pH sensing moiety). Conjugation of DCF to amino labeled DNA was confirmed by
 916 denaturing polyacrylamide gel electrophoresis. C2 is a 28 mer strand complementary to one half
 917 of C1 and is labeled with Atto 647N (pH and calcium insensitive dye) which acts as ratiometric
 918 moiety. C3 is a 30 mer strand which is complementary to the other half of C1. The formation of
 919 *ImLy2.0* was confirmed by mobility shift assay by native PAGE. *In vitro* calibration of *ImLy2.0*
 920 was performed by measuring the excitation and emission spectra in DCF (G) and Atto 647N (R)
 921 channels in universal buffer by varying pH ranging from pH 3.5 to pH 6.5. The ratio of G/R was
 922 plotted which was fitted to sigmoidal curve with Boltzmann fit. *In cellulo* calibration for *ImLy 2.0*

923 was performed in RAW 264.7 using protocol mentioned in the methods section. The R/G ratios
 924 were taken at single lysosomal resolution from cells treated clamped at varying pH. The ratios
 925 were plotted similar to *in vitro* calibration curve. The *in cellulo* calibration curve recapitulated *in*
 926 *vitro* calibration curve suggesting optimal sensing properties *in cellulo*. *ImLy2.0* was used to
 927 measure pH of both vesicular and tubular lysosomes in RAW 264.7 using the pH calibration curve
 928 generated using pH clamping of cells at varying pH points.
 929




930

931 **Figure. S25: Stability of DNA nanodevices in VEs and TLs** (a) Representative images of RAW
 932 264.7 cells showing dsDNA (Schematic shown in b) uptake containing PEG-Alexa 488 (G) and
 933 Atto 647N (R) at different indicated chase times. Scale bar: 5 μm . (b) Quantification showing
 934 whole cell intensities of G and R as a function of chase times. (n = 20 cells) (c) Representative
 935 single plane wide field images of *Tudor* treated RAW 264.7 labeled with *Tudor* containing Atto
 936 647N (R) and PEG-Alexa 488 (G) (Schematic shown in d) in TLs at various chase times. (d)
 937 Quantification showing normalized intensity of TLs in R and G channels at different chase times.
 938 (n = 15 cells, m = 50 TLs per experiment). Error bars indicate standard deviation (SD). Scale bar:
 939 10 μm . Data represented from three independent experiments.

940

941

942




943

944


945 **Figure. S26: pH and Calcium images of RAW 264.7.** (a-b) Representative images from *Tudor*
 946 treated RAW 264.7 cells pulsed with *CalipHluor 2.0* followed by chase in complete media (a),
 947 media containing 10 mM NH_4Cl (b). (c) Representative image of LPS treated RAW 264.7 cells
 948 pulsed with *CalipHluor 2.0* followed by chase in complete media. Pseudocolored maps of (i) G/R,
 949 (ii) pH, (iii), K_d , (iv) O/R (v) $\log [Ca^{2+}]$. Scale bar: 10 μm . (d, f) Schematic of the luminal pH and
 950 Ca^{2+} gradients in tubular lysosomes oriented from nucleus to plasma membrane (PM). (e, g) %
 951 TLs showing pH and calcium gradient as per schematic in (d, f), (n=15 cells; m=50 TLs.). All error
 952 bars represent s.e.m from three independent experiments unless otherwise mentioned.

953




954

955 **Figure. S27: Phagocytosis of zymosan particles in RAW 264.7 cells.** Representative widefield
 956 images of pHrodo™ Red labeled zymosan imaged at (a) pH 5.0 and (b) pH 7.2. (c) Representative
 957 fluorescence (left) and brightfield images (right) of RAW 264.7 cells with phagocytosed pHrodo™
 958 Red-zymosan. White arrowhead shows internalized zymosan. Yellow arrowhead shows the non-
 959 fluorescent zymosan outside the cells. Scale bar: 5µm. (d) Distribution of total cell intensity of
 960 fluid phase labeling of RAW 264.7 cells with Alexa 488 dextran. Cells were treated with either
 961 dsDNA, *Tudor* or LPS (n= 50 cells). Data represented from three independent experiments with
 962 similar results.



963

964 **Figure. S28: Phagocytic efficiency in M0, M1 and M2 macrophages of Pmacs.** (a-c)
 965 Representative widefield images of Pmacs showing pHrodo™ Red-zymosan uptake (fluorescence
 966 image, left and brightfield image, right). (d, e) Number of phagocytosed particles upon treatment
 967 with dsDNA or *Tudor* for 4 h. Arrowhead at t=0 min shows pHrodo™ Red-zymosan addition to
 968 cells (n = ~30 cells). Error bars represent s.e.m from 3 independent experiment. Scale bar: 10 µm.




970

971

972 **Figure. S29: Tudor regulates phagosome lysosome fusion in M0, M1 and M2 of Pmac.** (a, c
 973 and e) Representative confocal images of lysosomes marked with Alexa 488 conjugated dextran
 974 (G) and pHrodo™ Red conjugated zymosan (R) in Pmacs upon treatment with culture media
 975 (untreated); dsDNA, *Tudor*. (b) Zoomed image of white box containing # in (a) with white arrow
 976 heads showing TL contacting phagosome. (d and f) Quantification of mean G/R showing the
 977 phagosome lysosome fusion (P-L fusion) in P macs (n = 50 cells, ~300 phagosomes). (g, h and i)
 978 Total cell intensity of Alexa 488 dextran containing lysosomes in Pmacs upon treatment with
 979 dsDNA and *Tudor* (n=50 cells). All errors showed here represent s.e.m from three independent
 980 experiments. Scale bars: 10 μm.

981

982



983

984 **Figure. S30: Arl8b regulates Tudor mediated tubulation of lysosomes.** (a) Representative
 985 images of TMR dextran labeled lysosomes in *Tudor* or LPS treated RAW 264.7 transfected with
 986 scrambled siRNA and siRNA against *Arl8b* (si*Arl8b1* and si*Arl8b2*). Scale bar: 10 μ m, with inset
 987 scale bar: 4 μ m. * in inset represent VLs; # represents TLs. (b) Number of TLs per cell for (a),
 988 (n=20 cells). *** $P < 0.0005$; (one-way ANOVA with Tukey *post hoc* test). (c) Relative mRNA
 989 expression levels in RAW 264.7 treated with siRNA against *Arl8b* (si*Arl8b1* and si*Arl8b2*)
 990 normalized to expression levels of 18S rRNA used as negative control (NC). Error bars represent
 991 s.e.m. from 3 three independent experiments.

992 **Supplementary Note 8: Arl8b is essential for Tudor triggered tubulation of lysosomes:**


993 Lysosomal motility protein, Arl8b (ADP Ribosylation Factor like GTPase 8b) is a small Arf like
 994 GTPase which regulates the lysosomal positioning within the cytosol. Arl8b aids in lysosomal
 995 movement towards the periphery of the cell by governing the motility of lysosomes towards the
 996 “+” end of microtubule. This is due to its interaction with motor protein Kinesin1, through an
 997 adapter protein, SifA Kinesin interacting protein (SKIP)(38). Role of Arl8b in formation and
 998 movement of LPS triggered TLs is previously demonstrated(12, 39). To study if *Tudor* trigged
 999 TLs formation also involved the recruitment of Arl8b was studied in RAW 264.7 where the cells
 1000 were transfected with siRNA specific to Arl8b. Lysosomes in these cells were marked with TMR-
 1001 dextran followed by treatment with *Tudor* to trigger tubulation of lysosomes. TLs in these cells
 1002 were scored using Tubeness plugin as describes in Methods (Fig. S9). Cells treated with siRNA
 1003 for Arl8b showed drastically reduced TLs formation suggesting the involvement of Arl8b in *Tudor*
 1004 triggered TL formation (Fig. S30).

1005

1006

1007


1008




1009

1010 **Figure S31: Role of Arl8b, PI3K and mTOR in phagocytic uptake of zymosan in *Tudor***
 1011 **treated cells** (a) Representative images of *Tudor* treated RAW 264.7 cells showing its brightfield
 1012 image (left) and pHrodo™ Red conjugated zymosan as red (right) upon knocked down of Arl8b
 1013 and mentioned inhibitors. (b) Number of phagosomes in cells treated with indicated inhibitors,
 1014 (n=120 cells). ****P< 0.00005; (one-way ANOVA with Tukey *post hoc* test). Scale bar: 10 μ m.

1015




1016



1017


1018 **Figure. S32: Transcriptional expression of MMP9 is unperturbed in *Tudor* treated cells.** (a)
 1019 Representative images of TMR dextran labeled lysosomes in *Tudor* treated RAW 264.7 cells, in
 1020 presence or absence of Nrf2 and NFκB inhibitors. (b) Quantification showing the number of TLs
 1021 of (b). Error bars represent s.e.m from three independent experiments, (n =20 cells per experiment).
 1022 Scale bar: 10 μm; Inset scale bars: 4 μm. (c) Representative western blots of p-STAT1, p-NFκB
 1023 and tubulin in M0 BMDM treated with dsDNA or *Tudor* for 24 hours. M1 BMDMs are shown as
 1024 positive control for NFκB activation. (d) Expression levels of MMP9 in RAW 264.7 cells with or
 1025 without dsDNA or *Tudor* treatment at 4 and 24 hours, GAPDH as the loading control. (e and f)
 1026 Quantification showing the normalized intensity ratio of MMP9 to GAPDH at (e) 4 hrs and (f) 24
 1027 hrs. (one-way ANOVA with Tukey *post hoc* test), n.s: non-significant. Error bars represent s.e.m
 1028 from three independent experiments.

1029 **Supplementary note 9: Transcriptional activation of MMP9 is not observed in *Tudor* treated**
 1030 **cells.** We therefore tested whether MMP9 expression increased upon *Tudor* treatment, since
 1031 MMP9 transcription can be stimulated by either NF-κB or Nrf2. MMP9 can be activated upon
 1032 immunostimulation (75, 76) while the latter is activated during cell starvation or oxidative
 1033 stress(11, 77). Pharmacological inhibition of NF-κB and Nrf2 by JSH-23 and ML385 respectively
 1034 revealed no impact on *Tudor*-induced tubulation (Fig S32 a-b) (78, 79). *Tudor* treated M0 BMDM
 1035 showed no phosphorylation of NF-κβ or STAT1, reinforcing that *Tudor* does not trigger LPS-like
 1036 signaling or its associated transcriptional changes (Fig S32c). Further, *Tudor* treated RAW 264.7
 1037 cells showed no change in MMP9 mRNA levels, ruling out transcriptional regulation of MMP9
 1038 (Fig. 32d-f).




1039

1040 **Figure S33: Loss of lysosomal tubulation in MMP9 deficient BMDMs.** Representative confocal
 1041 images of Alexa 488 dextran (green) loaded lysosomes of M1 (a); M2 (b) and M0 (c) BMDM from
 1042 wildtype (WT) and MMP9 knockout (KO) mouse either untreated (UT) or treated with dsDNA
 1043 and *Tudor*. Inset showing the zoomed in area shown in the white box with * representing VLs and
 1044 # representing TLs. Scale bar 10 μm; Inset scale bar: 4 μm.



1045

1046 **Figure S34: MMP9 deficiency causes reduced phagocytosis.** (a) Representative confocal
 1047 images showing pHrodoTM red conjugated zymosan containing phagosomes in M1; M2 and M0
 1048 BMDMs from wildtypes (WT) and MMP9 KO origin treated with *Tudor*. Scale bar: 10 μm.



1049

1050 **Figure S35: Lack of MMP9 show reduced phagosome lysosome fusion in primary cells.** (a
 1051 and b) Representative confocal images of Alexa 488 dextran labeled lysosomes represented as
 1052 A488 (G), green; pHrodoTM red conjugated zymosan containing phagosome represented as pHrodo
 1053 (R), red and merge as yellow in BMDM (M2) either untreated (UT) or treatment with dsDNA or
 1054 *Tudor* from wildtype (a) and MMP9 knock out mouse origin (b) respectively. Scale bar: 10 μ m. (c
 1055 and d) Quantification showing total cell intensity of Alexa 488 dextran in BMDM (M2) of wildtype
 1056 and MMP9 KO origin.

Sequence name	DNA sequence information (5'-3')
SA43	ACGTTACTCTTGCAACACAAACTTTAATAGCCTCTTATAGTT C
A1	ACGTTACTCTTGCAACACAAACTTTAATAGCCTCTTATAGTT CTTCATCAACACTGCACACCAGACAGCA
A1-Atto647N	ACGTTACTCTTGCAACACAAACTTTAATAGCCTCTTATAGTT CTTCA/A647/TCAACACTGCACACCAGACAGCA
A2	TGCTGTCTGGTGTGCAGTGTTGAT
A3	ATCAACACTGCACACCAGACAGCA
A2-A647N	Alexa 647-TGCTGTCTGGTGTGCAGTGTTGAT
TRG2	GGCTATAGCACATGGGTAAAACGACTTTGCT/Alexa 647/TGCTGTCTGGTGTGCAGTGTTGAT
CpG	Atto 647- TGCTGTCTGGTGTGCAGTGTTGATTTtccatgacgttctctgacgtt
D1	DBCO- ATCAACACTGCACACCAGACAGCAAGATCCTATATATA

D2	Alexa 647- TATATATAGGATCTTGCTGTCTGGTGTGCAGTGTTGAT
C1	Amine- ATAACACATAACACATAACAAAATATATATCCTAGAACGAC AGACAAACAGTGAGTC
C2	ATTO647-TATATTTTGTATGTGTTATGTGTTAT
C3	DBCO-GACTCACTGTTTGTCTGTCGTTCTAGGATA
B1	ATCAACACTGCACACCAGACAGCAAGATCCTATATATAACT AC

1057 **Table S1:** List of DNA nanodevices used in the study

1058

1059 **Table S2:** Combinations of DNA used for specificity assays.

MUC1-dsDNA	5-TRG2 aptamer linked to A2+A3	1060
CpG-dsDNA	CpG strand linked to A2+ A3	
dsDNA	A2 and A3	1061
ssDNA	B1	1062

1063 **Table S3:** List of inhibitors used in the study.

Protein	Inhibitor	Concentration/duration	Cat no.	Source
TLR 4	TAK-242	10 μ M, 18 hours	13871	Cayman, USA
mTORC1	Rapamycin	100 nM, 1 hour	13346	Cayman, USA
mTORC2	Torin 1	100 nM, 1 hour	10997	Cayman, USA
AMPK	Dorsomorphin	20 μ M, 30 mins	21207	Cayman, USA
PI3K	Zstk474	1 μ M, 30 mins	17381	Cayman, USA
Akt	Akt inhibitor VIII	5 μ M, 30 mins	14870	Cayman, USA
Src1	Dasatinib	1 μ M, 1 hour	11498	Cayman, USA
JAK	JAK inhibitor I	1 μ M, 48 hours	15146	Cayman, USA
Rac1	NSC 23766	50 μ M, 12 hours	13196	Cayman, USA
TAK1	(5Z)-7-Oxo Zeaenol	300 nM, 6 hours	17459	Cayman, USA
PLD1	CAY10594	1 μ M, 30 mins	13207	Cayman, USA
MMP9	MMP9 inhibitor I	100 μ M, 1 hour	15942	Cayman, USA
Integrin 1	RGD peptide	0.3 mg/mL, 4 hours	14501	Cayman, USA
Pan Cathepsin	E64	50 μ M	10007963	Cayman, USA
TLR3	CuCPT-4a	27 μ M, 24 hours	4884	Tocris, USA
TLR5	TH 1020	0.37 μ M, 24 hours	6191	Tocris, USA
TLR2/6	GIT-27	10ug/mL, 24 hours	3270	Tocris

MYD88	MYD88 Inhibitor peptide	100 μ M, 24 hours	NBP-2 29328	Novus Biologicals, USA
LKB1	LKB1-i	380 nM, 24 hours	A3556	APExBio
IRS1	NT-157	1 μ M, 72 hours	S8228	Selleckchem
Sirtuin1	EX527	1 μ M, 24 hours	100099798	Cayman, USA
TLR1/2-i	CuCPT-22	8 μ M, 24 hours	4884	Tocris, USA
Nrf2	ML385	5 μ M, 72 hours	21114	Cayman, USA
NFkB	JSH-23	300 μ M, 1 hour	481408	Sigma Aldrich, USA
Dynamin (Endocytosis)	Dynasore	50 μ M, 1 hour	D7693	Sigma Aldrich, USA
DNA damage	Etoposide	50 μ M; 200 μ M, 1 hour	12092	Cayman, USA

1064

1065

1066

1067

Table S4. List of excitations, emission maxima of reagents used in the study along with the imaging filters used for its imaging in the confocal microscope.

Sl no.	Reagent Name.	Excitation maxima (nm)	Emission maxima (nm)	Excitation laser	Emission collection range (AOB settings) (nm)
1	ER Tracker TM Green	504	511	Argon laser 488 nm	515-550
2	Mito Tracker TM Green	490	516	Argon laser 488 nm	500-560
3	FITC dextran	490	520	Argon laser 488 nm	505-560
4	Alexa 488 dextran	495	519	Argon laser 488 nm	500-556
5	DCF	504	529	Argon laser 488 nm	512-560
6	Rhodamine 110	498	521	Argon laser 488 nm	504-562
7	TMR Dextran	555	580	DPSS laser, 561 nm	568-664
8	pHrodo TM Red	560	585	DPSS laser, 561 nm	570-610
9	Rhod-5F	560	580	DPSS laser, 561 nm	570-620
10	DQ TM BSA Red	590	620	HeNe laser 594 nm	600-660
11	Lyso Tracker TM deep red	647	668	HeNe laser 633 nm	660-737
12	Alexa 647	651	672	HeNe laser 633 nm	660-737
13	Atto 647N	646	667	HeNe laser 633 nm	650-700

1068

1069

Table S5: List of Reagents used in the study.

Reagents	Catalog number	Source
TMR conjugated 10kDa dextran	D1816	Thermo Fisher Scientific

FITC conjugated to 10 kDa dextran	FD10S	Thermo Fisher Scientific
Amino dextran 10kDa	D3330	Thermo Scientific
Zymosan A from <i>Cerevisiae</i>	Z4250	Sigma
LPS	2630	Sigma
Bafilomycin	B1793	Cayman Chemicals
Nigericin	11437	Cayman Chemicals
Ionomycin	I3909	Cayman Chemicals
Monensin Sodium	22373-78-0	Cayman Chemicals
40% Glyoxal solution	128465	Sigma
DQ TM BSA Red	D12051	Invitrogen
ER Tracker TM Green	E34251	Life technologies
LysoTracker TM Deep Red	L12492	Thermo Scientific
Mito Tracker TM Green	M7514	Thermo Scientific
SensoLyte 520 MMP9 assay Kit	AS-71155	AnaSpec Inc
5(6)-Carboxy-2',7'-dichlorofluorescein (DCF)	M1239	Abcam
DMEM	12400024	Life technologies
Opti-MEM TM	11058021	Life technologies
FBS	26140079	Gibco

1070

1071 **Table S6:** List of antibodies used in immunofluorescence study.

Antibodies	Catalog number	Source
Ku 70 (1:100)	NB100-1915	Novus Biologicals
Cathepsin B (1:100)	CST 31718	Cell Signaling technology
Lamp 1 (1:400)	ab24170	Abcam
Pan Cadherin (1:500)	ab16505	Abcam
PIP3(1:100)	Z-p345B	Echelon Biosciences

1072

1073 **Supplementary Video 1:** Timelapse images showing pH and Calcium gradient within the tubular
1074 lysosomes. Lysosomes in RAW 264.7 tubulated by *Tudor* and labeled with *CalipHluor 2.0* with
1075 change in pH in left and calcium on (right). Scale bar: 10 μ M.

1076

1077 Bibliography

- 1078 1. Prakash V, et al. (2019) Quantitative mapping of endosomal DNA processing by single
1079 molecule counting. *Angew Chem Int Ed Engl* 58(10):3073–3076.
- 1080 2. Modi S, et al. (2009) A DNA nanomachine that maps spatial and temporal pH changes
1081 inside living cells. *Nat Nanotechnol* 4(5):325–330.

- 1082 3. Saminathan A, et al. (2021) A DNA-based voltmeter for organelles. *Nat Nanotechnol*
1083 16(1):96–103.
- 1084 4. Kratz M, et al. (2014) Metabolic dysfunction drives a mechanistically distinct
1085 proinflammatory phenotype in adipose tissue macrophages. *Cell Metab* 20(4):614–625.
- 1086 5. Reardon CA, et al. (2018) Obesity and Insulin Resistance Promote Atherosclerosis through
1087 an IFN γ -Regulated Macrophage Protein Network. *Cell Rep* 23(10):3021–3030.
- 1088 6. Dan K, Veetil AT, Chakraborty K, Krishnan Y (2019) DNA nanodevices map enzymatic
1089 activity in organelles. *Nat Nanotechnol* 14(3):252–259.
- 1090 7. Leung K, Chakraborty K, Saminathan A, Krishnan Y (2019) A DNA nanomachine
1091 chemically resolves lysosomes in live cells. *Nat Nanotechnol* 14(2):176–183.
- 1092 8. Schindelin J, et al. (2012) Fiji: an open-source platform for biological-image analysis. *Nat*
1093 *Methods* 9(7):676–682.
- 1094 9. Narayanaswamy N, et al. (2019) A pH-correctable, DNA-based fluorescent reporter for
1095 organellar calcium. *Nat Methods* 16(1):95–102.
- 1096 10. Kalkofen DN, de Figueiredo P, Brown WJ (2015) Methods for analyzing the role of
1097 phospholipase A₂ enzymes in endosome membrane tubule formation. *Methods Cell Biol*
1098 130:157–180.
- 1099 11. Sato Y, et al. (1998) Three-dimensional multi-scale line filter for segmentation and
1100 visualization of curvilinear structures in medical images. *Med Image Anal* 2(2):143–168.
- 1101 12. Saric A, et al. (2016) mTOR controls lysosome tubulation and antigen presentation in
1102 macrophages and dendritic cells. *Mol Biol Cell* 27(2):321–333.
- 1103 13. Richter KN, et al. (2018) Glyoxal as an alternative fixative to formaldehyde in
1104 immunostaining and super-resolution microscopy. *EMBO J* 37(1):139–159.
- 1105 14. Hipolito VEB, et al. (2018) Lysosome expansion by selective translation of lysosomal
1106 transcripts during phagocyte activation. *BioRxiv*.
- 1107 15. Yoon DS, Choi Y, Lee JW (2016) Cellular localization of NRF2 determines the self-
1108 renewal and osteogenic differentiation potential of human MSCs via the P53-SIRT1 axis.
1109 *Cell Death Dis* 7:e2093.
- 1110 16. Adamczyk M, Fishpaugh JR, Heuser KJ (1997) Preparation of succinimidyl and
1111 pentafluorophenyl active esters of 5- and 6-carboxyfluorescein. *Bioconjug Chem* 8(2):253–
1112 255.
- 1113 17. Moore D (2001) Purification and concentration of DNA from aqueous solutions. *Curr*
1114 *Protoc Immunol* Chapter 10:Unit 10.1.
- 1115 18. Chakraborty K, Leung K, Krishnan Y (2017) High luminal chloride in the lysosome is
1116 critical for lysosome function. *Elife* 6:e28862.

- 1117 19. Veetil AT, Jani MS, Krishnan Y (2018) Chemical control over membrane-initiated steroid
1118 signaling with a DNA nanocapsule. *Proc Natl Acad Sci USA* 115(38):9432–9437.
- 1119 20. Lahann J ed. (2009) *Click chemistry for biotechnology and materials science* (John Wiley
1120 & Sons, Ltd, Chichester, UK).
- 1121 21. Monferran S, Paupert J, Dauvillier S, Salles B, Muller C (2004) The membrane form of the
1122 DNA repair protein Ku interacts at the cell surface with metalloproteinase 9. *EMBO J*
1123 23(19):3758–3768.
- 1124 22. Chan YGY, Cardwell MM, Hermanas TM, Uchiyama T, Martinez JJ (2009) Rickettsial
1125 outer-membrane protein B (rOmpB) mediates bacterial invasion through Ku70 in an actin,
1126 c-Cbl, clathrin and caveolin 2-dependent manner. *Cell Microbiol* 11(4):629–644.
- 1127 23. Monferran S, Muller C, Mourey L, Frit P, Salles B (2004) The Membrane-associated form
1128 of the DNA repair protein Ku is involved in cell adhesion to fibronectin. *J Mol Biol*
1129 337(3):503–511.
- 1130 24. Prabhakar BS, Allaway GP, Srinivasappa J, Notkins AL (1990) Cell surface expression of
1131 the 70-kD component of Ku, a DNA-binding nuclear autoantigen. *J Clin Invest*
1132 86(4):1301–1305.
- 1133 25. Aptekar S, et al. (2015) Selective Targeting to Glioma with Nucleic Acid Aptamers. *PLoS*
1134 *One* 10(8):e0134957.
- 1135 26. Jani MS, Zou J, Veetil AT, Krishnan Y (2020) A DNA-based fluorescent probe maps
1136 NOS3 activity with subcellular spatial resolution. *Nat Chem Biol* 16(6):660–666.
- 1137 27. Ferreira CSM, Cheung MC, Missailidis S, Bisland S, Gariépy J (2009) Phototoxic
1138 aptamers selectively enter and kill epithelial cancer cells. *Nucleic Acids Res* 37(3):866–
1139 876.
- 1140 28. West AP, Koblansky AA, Ghosh S (2006) Recognition and signaling by toll-like receptors.
1141 *Annu Rev Cell Dev Biol* 22:409–437.
- 1142 29. Veetil AT, et al. (2020) DNA-based fluorescent probes of NOS2 activity in live brains.
1143 *Proc Natl Acad Sci USA* 117(26):14694–14702.
- 1144 30. Li X, et al. (2016) A molecular mechanism to regulate lysosome motility for lysosome
1145 positioning and tubulation. *Nat Cell Biol* 18(4):404–417.
- 1146 31. Murakawa T, Kiger AA, Sakamaki Y, Fukuda M, Fujita N (2020) An Autophagy-
1147 Dependent Tubular Lysosomal Network Synchronizes Degradative Activity Required for
1148 Muscle Remodeling. *BioRxiv*.
- 1149 32. Jiang T, et al. (2015) p62 links autophagy and Nrf2 signaling. *Free Radic Biol Med* 88(Pt
1150 B):199–204.

- 1151 33. Jain A, et al. (2010) p62/SQSTM1 is a target gene for transcription factor NRF2 and
1152 creates a positive feedback loop by inducing antioxidant response element-driven gene
1153 transcription. *J Biol Chem* 285(29):22576–22591.
- 1154 34. Komatsu M, et al. (2010) The selective autophagy substrate p62 activates the stress
1155 responsive transcription factor Nrf2 through inactivation of Keap1. *Nat Cell Biol*
1156 12(3):213–223.
- 1157 35. Fan W, et al. (2010) Keap1 facilitates p62-mediated ubiquitin aggregate clearance via
1158 autophagy. *Autophagy* 6(5):614–621.
- 1159 36. Copple IM, et al. (2010) Physical and functional interaction of sequestosome 1 with Keap1
1160 regulates the Keap1-Nrf2 cell defense pathway. *J Biol Chem* 285(22):16782–16788.
- 1161 37. Yu L, et al. (2010) Termination of autophagy and reformation of lysosomes regulated by
1162 mTOR. *Nature* 465(7300):942–946.
- 1163 38. Khatler D, Sindhvani A, Sharma M (2015) Arf-like GTPase Arl8: Moving from the
1164 periphery to the center of lysosomal biology. *Cell Logist* 5(3):e1086501.
- 1165 39. Kaniuk NA, et al. (2011) Salmonella exploits Arl8B-directed kinesin activity to promote
1166 endosome tubulation and cell-to-cell transfer. *Cell Microbiol* 13(11):1812–1823.
- 1167